CA2522294A1 - Formulations and methods for treating rhinosinusitis - Google Patents
Formulations and methods for treating rhinosinusitis Download PDFInfo
- Publication number
- CA2522294A1 CA2522294A1 CA002522294A CA2522294A CA2522294A1 CA 2522294 A1 CA2522294 A1 CA 2522294A1 CA 002522294 A CA002522294 A CA 002522294A CA 2522294 A CA2522294 A CA 2522294A CA 2522294 A1 CA2522294 A1 CA 2522294A1
- Authority
- CA
- Canada
- Prior art keywords
- particle size
- steroidal anti
- microns
- less
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 229
- 238000009472 formulation Methods 0.000 title claims abstract description 222
- 201000009890 sinusitis Diseases 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 56
- 239000002245 particle Substances 0.000 claims abstract description 408
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 46
- 239000003429 antifungal agent Substances 0.000 claims abstract description 43
- 241000233866 Fungi Species 0.000 claims abstract description 36
- 238000009826 distribution Methods 0.000 claims abstract description 34
- 230000003115 biocidal effect Effects 0.000 claims abstract description 32
- 241000124008 Mammalia Species 0.000 claims abstract description 19
- 230000003637 steroidlike Effects 0.000 claims description 165
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 150
- 150000003431 steroids Chemical class 0.000 claims description 55
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 37
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 26
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 25
- 229960000289 fluticasone propionate Drugs 0.000 claims description 25
- 210000004877 mucosa Anatomy 0.000 claims description 25
- 239000003242 anti bacterial agent Substances 0.000 claims description 18
- 239000007921 spray Substances 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 17
- -1 Aztreonan Chemical compound 0.000 claims description 15
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 15
- 229960004884 fluconazole Drugs 0.000 claims description 15
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 15
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 12
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 11
- 229940092705 beclomethasone Drugs 0.000 claims description 11
- 229960004130 itraconazole Drugs 0.000 claims description 11
- 229940053050 neomycin sulfate Drugs 0.000 claims description 11
- 229960002714 fluticasone Drugs 0.000 claims description 10
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 9
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 208000035143 Bacterial infection Diseases 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 8
- 239000008121 dextrose Substances 0.000 claims description 8
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 239000007900 aqueous suspension Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229940067107 phenylethyl alcohol Drugs 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 229930183010 Amphotericin Natural products 0.000 claims description 4
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 4
- 229940009444 amphotericin Drugs 0.000 claims description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 4
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229960004489 cefonicid Drugs 0.000 claims description 3
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 claims description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 3
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229960000707 tobramycin Drugs 0.000 claims description 3
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims description 2
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 claims description 2
- 229960004821 amikacin Drugs 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- 229960004350 cefapirin Drugs 0.000 claims description 2
- 229960001139 cefazolin Drugs 0.000 claims description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 2
- 229960004261 cefotaxime Drugs 0.000 claims description 2
- 229960005495 cefotetan Drugs 0.000 claims description 2
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 claims description 2
- 229960002682 cefoxitin Drugs 0.000 claims description 2
- 229960001668 cefuroxime Drugs 0.000 claims description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 2
- 229960000318 kanamycin Drugs 0.000 claims description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
- 229960003907 linezolid Drugs 0.000 claims description 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims description 2
- 229960000515 nafcillin Drugs 0.000 claims description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims description 2
- 229960001019 oxacillin Drugs 0.000 claims description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 2
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 claims description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-UPWJBAEMSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaen Chemical group OC1C(N)C(O)C(C)OC1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-UPWJBAEMSA-N 0.000 claims 7
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 claims 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930193140 Neomycin Natural products 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 claims 1
- 229960001991 ceftizoxime Drugs 0.000 claims 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 claims 1
- 229960004755 ceftriaxone Drugs 0.000 claims 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 229960002227 clindamycin Drugs 0.000 claims 1
- 229960003722 doxycycline Drugs 0.000 claims 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 1
- 229960004213 erythromycin lactobionate Drugs 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 229960000198 mezlocillin Drugs 0.000 claims 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims 1
- 229960003128 mupirocin Drugs 0.000 claims 1
- 229930187697 mupirocin Natural products 0.000 claims 1
- 229960004927 neomycin Drugs 0.000 claims 1
- 229960001914 paromomycin Drugs 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 1
- 239000004576 sand Substances 0.000 claims 1
- 229960005322 streptomycin Drugs 0.000 claims 1
- 229960004659 ticarcillin Drugs 0.000 claims 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 32
- 239000002294 steroidal antiinflammatory agent Substances 0.000 abstract description 4
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 18
- 102220313493 rs746811389 Human genes 0.000 description 18
- 239000004615 ingredient Substances 0.000 description 14
- 230000002538 fungal effect Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 210000003097 mucus Anatomy 0.000 description 12
- 239000008186 active pharmaceutical agent Substances 0.000 description 11
- 239000003443 antiviral agent Substances 0.000 description 11
- 229940088679 drug related substance Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- 239000002260 anti-inflammatory agent Substances 0.000 description 9
- 229940121363 anti-inflammatory agent Drugs 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000000592 Nasal Polyps Diseases 0.000 description 6
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 6
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 208000037062 Polyps Diseases 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000000843 anti-fungal effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 3
- 241000581364 Clinitrachus argentatus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010028748 Nasal obstruction Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000850 decongestant Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 229940041033 macrolides Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000223 polyglycerol Chemical class 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102220226091 rs1064794928 Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- NZKFUBQRAWPZJP-BXKLGIMVSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NZKFUBQRAWPZJP-BXKLGIMVSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- KGFBVQXWAXWGDL-UHFFFAOYSA-N 1,4-dihydro-2,3-benzodithiine Chemical compound C1=CC=C2CSSCC2=C1 KGFBVQXWAXWGDL-UHFFFAOYSA-N 0.000 description 2
- AJZDKCDLDNDFBE-KQYNXXCUSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazole-3,4-dicarboxamide Chemical compound N1=C(C(N)=O)C(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 AJZDKCDLDNDFBE-KQYNXXCUSA-N 0.000 description 2
- QZKOOEFIMWKZPK-UHFFFAOYSA-N 2-[(6-carbamimidoyl-1h-benzimidazol-2-yl)methyl]-3h-benzimidazole-5-carboximidamide Chemical compound C1=C(C(N)=N)C=C2NC(CC3=NC4=CC=C(C=C4N3)C(=N)N)=NC2=C1 QZKOOEFIMWKZPK-UHFFFAOYSA-N 0.000 description 2
- PPJYSSNKSXAVDB-UHFFFAOYSA-N 3,3',5,5'-tetraiodothyroacetic acid Chemical compound IC1=CC(CC(=O)O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 PPJYSSNKSXAVDB-UHFFFAOYSA-N 0.000 description 2
- NZVORGQIEFTOQZ-UHFFFAOYSA-N 9-[2-(phosphonomethoxy)ethyl]guanine Chemical compound N1C(N)=NC(=O)C2=C1N(CCOCP(O)(O)=O)C=N2 NZVORGQIEFTOQZ-UHFFFAOYSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
- FRPXSOOHWNMLPH-LURJTMIESA-N [(2s)-1-(6-aminopurin-9-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid Chemical compound NC1=NC=NC2=C1N=CN2C[C@@H](CO)OCP(O)(O)=O FRPXSOOHWNMLPH-LURJTMIESA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 2
- 229940047524 ceptaz Drugs 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940063193 cleocin Drugs 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229940124581 decongestants Drugs 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 229960000676 flunisolide Drugs 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 229940099584 lactobionate Drugs 0.000 description 2
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229940021422 maxipime Drugs 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 229940066491 mucolytics Drugs 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 description 2
- 239000001589 sorbitan tristearate Substances 0.000 description 2
- 229960004129 sorbitan tristearate Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 150000003899 tartaric acid esters Chemical class 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 2
- 229960004740 voriconazole Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical class CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- SWQQELWGJDXCFT-PNHWDRBUSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole-4-carboxamide Chemical compound C#CC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SWQQELWGJDXCFT-PNHWDRBUSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- DRZJQJUHRYWLSR-UHFFFAOYSA-N 2,3-dihydroxy-4-octadecanoyloxy-4-oxobutanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)C(O)C(O)C(O)=O DRZJQJUHRYWLSR-UHFFFAOYSA-N 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000223208 Curvularia Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000294754 Macroptilium atropurpureum Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- XESARGFCSKSFID-UHFFFAOYSA-N Pyrazofurin Natural products OC1=C(C(=O)N)NN=C1C1C(O)C(O)C(CO)O1 XESARGFCSKSFID-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 1
- VXDNQJCXIVLMQW-UHFFFAOYSA-N [1-(2-amino-6-oxo-3h-purin-9-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid Chemical compound N1C(N)=NC(=O)C2=C1N(CC(CO)OCP(O)(O)=O)C=N2 VXDNQJCXIVLMQW-UHFFFAOYSA-N 0.000 description 1
- VWFCHDSQECPREK-UHFFFAOYSA-N [1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid Chemical compound NC=1C=CN(CC(CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-UHFFFAOYSA-N 0.000 description 1
- 235000010937 acetic acid esters of mono- and di- glycerides of fatty acids Nutrition 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940112258 acular Drugs 0.000 description 1
- SUPKOOSCJHTBAH-UHFFFAOYSA-N adefovir Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019824 amidated pectin Nutrition 0.000 description 1
- YUCHAYRHHXJNQK-UHFFFAOYSA-N amitivir Chemical compound N#CNC1=NN=CS1 YUCHAYRHHXJNQK-UHFFFAOYSA-N 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 239000001809 ammonium phosphatide Substances 0.000 description 1
- 235000010986 ammonium phosphatide Nutrition 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940089206 anhydrous dextrose Drugs 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940058060 astelin Drugs 0.000 description 1
- 229940098165 atrovent Drugs 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940028420 bactroban Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 description 1
- 239000003916 calcium stearoyl-2-lactylate Substances 0.000 description 1
- OEUVSBXAMBLPES-UHFFFAOYSA-L calcium stearoyl-2-lactylate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O OEUVSBXAMBLPES-UHFFFAOYSA-L 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229940105726 cefotan Drugs 0.000 description 1
- 229940047496 ceftin Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- KEWHKYJURDBRMN-XSAPEOHZSA-M chembl2134724 Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-XSAPEOHZSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- UUAGAQFQZIEFAH-UHFFFAOYSA-N chlorotrifluoroethylene Chemical group FC(F)=C(F)Cl UUAGAQFQZIEFAH-UHFFFAOYSA-N 0.000 description 1
- 229960004375 ciclopirox olamine Drugs 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 235000010939 citric acid esters of mono- and di- glycerides of fatty acids Nutrition 0.000 description 1
- 229940088530 claforan Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
- 229960002030 edoxudine Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 210000001180 ethmoid sinus Anatomy 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 229940072686 floxin Drugs 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
- 229940089936 fortaz Drugs 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229960001906 haloprogin Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 235000010938 lactic acid esters of mono- and di- glycerides of fatty acids Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000003701 mechanical milling Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229940000973 monistat Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 229940072709 motrin Drugs 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- JQEKDNLKIVGXAU-UHFFFAOYSA-L nedocromil sodium Chemical compound [Na+].[Na+].CCN1C(C([O-])=O)=CC(=O)C2=C1C(CCC)=C1OC(C([O-])=O)=CC(=O)C1=C2 JQEKDNLKIVGXAU-UHFFFAOYSA-L 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940028429 otrivin Drugs 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000010178 pectin extract Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229950005137 saperconazole Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000002398 sedimentation field-flow fractionation Methods 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 1
- 235000010956 sodium stearoyl-2-lactylate Nutrition 0.000 description 1
- 239000003724 sodium stearoyl-2-lactylate Substances 0.000 description 1
- 235000010950 sodium, potassium and calcium salts of fatty acids Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003718 sphenoid sinus Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000001957 sucroglyceride Chemical class 0.000 description 1
- 235000010964 sucroglyceride Nutrition 0.000 description 1
- 239000001959 sucrose esters of fatty acids Chemical class 0.000 description 1
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960004267 taurolidine Drugs 0.000 description 1
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960000699 terbinafine hydrochloride Drugs 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 150000005672 tetraenes Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940032699 vistide Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229940072251 zithromax Drugs 0.000 description 1
- 229940061740 zyvox Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/0035—Gamma radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/04—Heat
- A61L2/06—Hot gas
- A61L2/07—Steam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Abstract
The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile . The formulation may also comprise an antifungal agent, antibiotic or antivir al agent.
Description
FORMULATIONS AND METHODS FOR TREATING RHINOSINUSITIS
I. RELATED APPLICATIONS
The present application is a continuation-in-part of Application Serial Nos.
141414,682 and Application Serial No. 10/414,756. Both applications were filed April 16, 2003. Each application is incorporated herein by reference in its entirety.
II. FIELD OF THE INVENTION
The present invention relates to formulations and methods for treating rhinosinusitis in mammals (e.g., humans), including but not limited to fungus induced rhinosinusitis. . The formulations of the present invention comprise a steroidal agent, such as fluticasone or beclomethasone, wherein the steroidal agent has a specific particle size distribution profile. The formulations may also comprise an antibiotic, antifungal agent or an antiviral agent, or any combination thereof. While the formulations of the present invention may take any form, preferably they are provided as a sterile, aqueous suspension or solution which can be administered intranasally to the nasal-paranasal mucosa via spray pump. Also, the steroidal agent may be administered alone or in conjunction with an antifungal agent, antibiotic or antiviral agent.
III. BACKGROUND OF THE INVENTION
Rhinosinusitis is generally described as an inflammation of the nasal cavity andlor paranasal sinuses and involves the nasal mucosa. Chronic rhinosinusitis (CRS) is diagnosed when signs or symptoms of inflammation persist for 8-12 weeks or longer. It is estimated that one out of every seven Americans suffers from chronic rhinosinusitis (CRS}. Symptoms of CRS include nasal obstruction, loss of sense of smell, nasal or postnasal discharge, nasal congestion, and facial painlpressure (typically over the affected sinus area).
CRS impairs normal physical and social functioning, and patients with CRS
typically suffer from an overall poor quality of life. Moreover, CRS is often associated with other co-morbid conditions such as asthma, eczema and other media. Asthma is found in 20-35% ofpatients with CRS, and CRS is found in up to 75% ofmoderate-to severe asthmatics.
It is now known that rhinosinusitis may be caused by fungi found in mucus. It is believed that some persons have an immunologic response to certain fungi found in most, if not all, persons' mucus. This immunologic response causes activated white blood cells, eosinophils, to enter the mucus. The activated eosinophils release a major basic toxic protein into the mucus which attacks and kills the fungi, but damages the nose and sinus membranes as well.. The major basic protein also injures the epithelium, which allows bacteria to infect the tissues.
One type of fungus-induced rhinosinusitis is allergic fungus rhinosinusitis (AFS).
AFS is generally diagnosed by: (1) the presence of nasal polyps; (2) allergic mucin; (3) CRS evidenced by CT scan; (4) positive fungal culture or histology; and/or (5) allergy to fungi by history, skin prick test or serology., AFS often leads to or is associated with CRS.
Current treatments for fungus induced rhinosinusitis include antifungal medications to remove the antigenic burden. A topical or systenuc corticosteroid may also be prescribed to control inflammation of the mucosal tissue associated with CRS.
This inflammation is thought to contribute to tissue and bone destruction associated with
I. RELATED APPLICATIONS
The present application is a continuation-in-part of Application Serial Nos.
141414,682 and Application Serial No. 10/414,756. Both applications were filed April 16, 2003. Each application is incorporated herein by reference in its entirety.
II. FIELD OF THE INVENTION
The present invention relates to formulations and methods for treating rhinosinusitis in mammals (e.g., humans), including but not limited to fungus induced rhinosinusitis. . The formulations of the present invention comprise a steroidal agent, such as fluticasone or beclomethasone, wherein the steroidal agent has a specific particle size distribution profile. The formulations may also comprise an antibiotic, antifungal agent or an antiviral agent, or any combination thereof. While the formulations of the present invention may take any form, preferably they are provided as a sterile, aqueous suspension or solution which can be administered intranasally to the nasal-paranasal mucosa via spray pump. Also, the steroidal agent may be administered alone or in conjunction with an antifungal agent, antibiotic or antiviral agent.
III. BACKGROUND OF THE INVENTION
Rhinosinusitis is generally described as an inflammation of the nasal cavity andlor paranasal sinuses and involves the nasal mucosa. Chronic rhinosinusitis (CRS) is diagnosed when signs or symptoms of inflammation persist for 8-12 weeks or longer. It is estimated that one out of every seven Americans suffers from chronic rhinosinusitis (CRS}. Symptoms of CRS include nasal obstruction, loss of sense of smell, nasal or postnasal discharge, nasal congestion, and facial painlpressure (typically over the affected sinus area).
CRS impairs normal physical and social functioning, and patients with CRS
typically suffer from an overall poor quality of life. Moreover, CRS is often associated with other co-morbid conditions such as asthma, eczema and other media. Asthma is found in 20-35% ofpatients with CRS, and CRS is found in up to 75% ofmoderate-to severe asthmatics.
It is now known that rhinosinusitis may be caused by fungi found in mucus. It is believed that some persons have an immunologic response to certain fungi found in most, if not all, persons' mucus. This immunologic response causes activated white blood cells, eosinophils, to enter the mucus. The activated eosinophils release a major basic toxic protein into the mucus which attacks and kills the fungi, but damages the nose and sinus membranes as well.. The major basic protein also injures the epithelium, which allows bacteria to infect the tissues.
One type of fungus-induced rhinosinusitis is allergic fungus rhinosinusitis (AFS).
AFS is generally diagnosed by: (1) the presence of nasal polyps; (2) allergic mucin; (3) CRS evidenced by CT scan; (4) positive fungal culture or histology; and/or (5) allergy to fungi by history, skin prick test or serology., AFS often leads to or is associated with CRS.
Current treatments for fungus induced rhinosinusitis include antifungal medications to remove the antigenic burden. A topical or systenuc corticosteroid may also be prescribed to control inflammation of the mucosal tissue associated with CRS.
This inflammation is thought to contribute to tissue and bone destruction associated with
2 CRS. Recently, it has been discovered that steroidal anti-inflammatories such as fluticasone propionate (FP) and beclomethasone dipropionate (BDP) having a particular particle size distribution profile provide increased bioavailability, increased efficacy and/or prolonged therapeutic effect when administered intranasally.
CRS may also be characterized by or associated with a chronic bacterial infection of the sinuses (nasal-paranasal region) which is often superimposed upon a self perpetuating, eosinophii-rich inflammatory process in the sinuses. Currently, antibiotic therapy is indicated for up to six weeks or more for the treatment~and elimination of the bacterial infection associated with CRS.
IV. SUMMARY OF INVENTION
' The present invention relates generally to formulations and methods for treating rhinosinusitis in mammals (e.g., humans), including, but not limited to fungus-induced rhinosinusitis. In one embodiment, the formulations of the present invention comprise a steroid, alone or in combination with an antifungal agent or antibiotic. It is believed that treating the patient with an antifungal agent will sufficiently reduce the level of fungal organisms in the patient's mucus such that the one ore more of the symptoms of rhinosinusitis are prevented from developing or are lessened, or are prevented from worsening.
In an embodiment, the present formulations comprise about 4 mg to about 30 mg of the anti-fungal agent ~amphotericin ~. In an alternative embodiment, the formulation of the present invention comprises about 20 to about 70 mg of the anti-fungal agent fluconazole or itraconazole.
CRS may also be characterized by or associated with a chronic bacterial infection of the sinuses (nasal-paranasal region) which is often superimposed upon a self perpetuating, eosinophii-rich inflammatory process in the sinuses. Currently, antibiotic therapy is indicated for up to six weeks or more for the treatment~and elimination of the bacterial infection associated with CRS.
IV. SUMMARY OF INVENTION
' The present invention relates generally to formulations and methods for treating rhinosinusitis in mammals (e.g., humans), including, but not limited to fungus-induced rhinosinusitis. In one embodiment, the formulations of the present invention comprise a steroid, alone or in combination with an antifungal agent or antibiotic. It is believed that treating the patient with an antifungal agent will sufficiently reduce the level of fungal organisms in the patient's mucus such that the one ore more of the symptoms of rhinosinusitis are prevented from developing or are lessened, or are prevented from worsening.
In an embodiment, the present formulations comprise about 4 mg to about 30 mg of the anti-fungal agent ~amphotericin ~. In an alternative embodiment, the formulation of the present invention comprises about 20 to about 70 mg of the anti-fungal agent fluconazole or itraconazole.
3 The present invention is also based on the realization that a patient or individual may have already developed one or more symptoms of rhinosinusitis, possibly CRS, when he or she first seeks the help of a physician or by the time that treatment is started.
Thus, it would also be beneficial to provide an anti-inflammatory steroid to the patient to treat inflammation of the mucosal tissue associated with rhinosinusitis, since such inflammation might lead to or contribute to tissue and bone destruction in the nasal-paranasal region.
It has recently been discovered that certain steroidal anti-inflammatories having a specific particle size distribution profile provide increased bioavailability, increased efficacy or prolonged therapeutic effect when administered intranasally. In one embodiment, the formulation of the present invention comprises about 25 to about 400 mcg of the steroidal anti-inflammatory agent, including but not limited to, fluticasone, or a pharmaceutically acceptable derivative thereof, having the following particle size distribution profile: about 10% of the drug substance particles have a particle size of about 0.90 microns; about than.25% of the drug substance particles have a particle size of less than 1.6 microns;.about 50% of the drug substance particles have a particle size of less than 3.2 microns; about 75% of the drug substance particles have a particle size of less than 6.10 microns; about 90% of the drug substance particles have a particle size of less than 10.0 microns.
In an alternative embodiment, the formulation of the present invention comprises about 0.2 to about 3 mg of the steroidal anti-inflammatory beclomethasone, or a pharmaceutically acceptable derivative thereof, having the following particle size distribution profile: about 10% of the drug substance particles have a particle size of
Thus, it would also be beneficial to provide an anti-inflammatory steroid to the patient to treat inflammation of the mucosal tissue associated with rhinosinusitis, since such inflammation might lead to or contribute to tissue and bone destruction in the nasal-paranasal region.
It has recently been discovered that certain steroidal anti-inflammatories having a specific particle size distribution profile provide increased bioavailability, increased efficacy or prolonged therapeutic effect when administered intranasally. In one embodiment, the formulation of the present invention comprises about 25 to about 400 mcg of the steroidal anti-inflammatory agent, including but not limited to, fluticasone, or a pharmaceutically acceptable derivative thereof, having the following particle size distribution profile: about 10% of the drug substance particles have a particle size of about 0.90 microns; about than.25% of the drug substance particles have a particle size of less than 1.6 microns;.about 50% of the drug substance particles have a particle size of less than 3.2 microns; about 75% of the drug substance particles have a particle size of less than 6.10 microns; about 90% of the drug substance particles have a particle size of less than 10.0 microns.
In an alternative embodiment, the formulation of the present invention comprises about 0.2 to about 3 mg of the steroidal anti-inflammatory beclomethasone, or a pharmaceutically acceptable derivative thereof, having the following particle size distribution profile: about 10% of the drug substance particles have a particle size of
4 about 0.75 microns; about than 25% of the drug substance particles have a particle size of Iess than 1.5 microns; about 50% of the drug substance particles have a particle size of less than 2.0 microns; about 75% of the drug substance particles have a particle size of less than 3.5 microns; about 90% of the drug substance particles have a particle size of less than 5.0 microns; and, greater than 90% or about 100% of the drug substance particles have a particle size of less than 10 microns.
In many instances the fungus-induced rhinosinusitis may be accompanied by, or associated with, a bacterial infection of the nasal-paranasal mucosa. In one embodiment, the fonnulations of the present invention comprise an antibiotic. In an alternative embodiment, the present formulations comprise about 1 to about 800 mg of the antibiotic neomycin sulfate.
The formulations of the present invention may be provided in any form which directly contacts the formulation with the nasal-paranasal mucosa. In one embodiment, the present formulation is provided as a sterile aqueous solution or.
suspension. In an alternative embodiments the formulation is in a metered dose spray pump.
The.present invention also generally relates to methods for treating rhinosinusitis, including fungus-induced rhinosinusitis. In one alternative embodiment, an individual suffering from rhinosinusitis may be administered a steroidal agent of the, present invention alone, or in combination or conjunction with an anti-fungal agent, antibiotic or antiviral agent. For example, the steroidal agent may be administered separately from the anti-fungal agent or antibiotic, or each of these ingredients may be administered simultaneously (e.g., in a single formulation) or individually, concurrently, in tandem or subsequently relative to each other, or in any combination thereof.
Y. DETAILED DISCUSSION OF THE IIVYENTION
The present invention is directed to formulations for the treatment of one or more symptoms of rhinosinusitis in an individual, lZhinosinusitis occurs in the nasal paranasal region. Symptoms of rhinosinusitis include, without limitation, facial pain, pressure, and/or fullness; loss of smell; nasal obstruction or blockage; nasal or postnasal discharge;
rhinorrhea; hyposimia/ansomnia; fever; headaches; halitosis; fatigue; dental pain; cough;
and ear pain, pressure, and/or fullness. Upon examination, the presence of thick mucus or the visual identification of nasal or paranasal obstruction with mucus or polyps often indicates a rhinosinusitis condition.
Nasal polyps may also be associated with or indicative of rhinosinusitis.
Nasal polyps are outgrowths from the nasal-paranasal mucosa that are typically smooth, gelatinous, semitranslucent, round or pear shaped, and pale. In general, nasal polyps are located on the lateral wall of the nose, usually in the middle meatus or along the middle and superior tuxbinates. Most nasal polyps arise from the ethmoid sinus but some polyps originate in the maxillary sphenoid sinuses. The mass of a nasal.polyp is composed mainly of edematous fluid with sparse fibrous cells and a few mucous glands.
The surface epithelium of nasal and paranasal polyps generally reveals squamous metaplasia.
Eosinophils are usually present in polyps in moderate to large numbers, and it is now known that nasal polyp fluid contains greater than normal concentrations of IgA, IgE, IgG, and IgM antibodies as well as abnormally high concentrations of IL-5, a cytokine that contributes to eosinophil activation and survival.
It is understood that the scope of the invention is directed to the treatment of rhinosinusitis including, but.not limited to, any rhinosinusitis condition, including, but not limited to, acute, subacute, recurrent acute and chronic rhinosinusitis, which may be accompanied by, aggravated by, associated with or caused by (in whole or in part) fungi, viruses, or microorganisms in the mucosa. For example, rhinosinusitis may include fungus-induced rhinosinusitis caused by, for example, an immunologic response to mucosal fungi or other organism. In one alternative enibodiment, the fungus-induced rhinosinusitis is allergic fungal rhinosinusitis, or AFS.
Formulation In one alternative embodiment, the present invention is directed to formulations for the treatment of rhinosinusitis. In one embodiment, the formulations comprise a steroidal anti-inflammatory, alone or in combination with an antifungal agent, antibiotic or antiviral~ agent. As used herein, treatment means the prophylaxis, prevention or amelioration of one or more symptoms of, or associated with, rhinosinusitis, or any manner in which one or more of the symptoms of, or associated with, rhinosinusitis are beneficially altered or are prevented from worsening. . As used herein, amelioration means any lessening, whether permanent or temporary, lasting or transient, of one or more symptoms of rhinosinusitis, including but not limited to fungus-induced rhinosinusitis.
Antifun~al Aeent Antifungal agents for use herein include any agent effective in treating rhinosinusitis, including fungus-induced rhinosinusitis. Preferably, the antifungal agent of the present formulations reduces the presence of fungal organisms within mucus to a level such that the characteristic inflammatory responses and resulting damages associated with fungal induced rhinosinusitis are lessened, whether permanent or temporary, lasting or transient, stopped, treated, or prevented.
For example, in one alternative embodiment of the present invention, an antifungal agent for. use herein may include any agent that prevents the growth of or kills a fungal organism such as antifungal polyene macrolides, tetraene macrolides, pentaenic macrolides, fluorinated pyrimidines, imidazoles, triazoles, azoles, halogenated phenolic ethers, thiocarbamates, and allylamines, and other. In addition, antifungal agents can be agents that interpolate fungal cell wall components or act as sterol inhibitors. Specific antifungal agents within the scope of the invention include, without limitation, amphotericin Vii, flucytosine, ketoconazole, miconazole, itraconazole, fluconazole, griseofulvin, clotrimazole, econazole, terconazole, butoconazole, oxiconazole, sulconazole, saperconazole, voricona2ole, ciclopirox olamine, haloprogin, tolnaftate, naftifine, nystatin, natamycin, terbinafine hydrochloride, morpholines, butenafine undecylenic acid, Whitefield's ointment, propionic acid, and caprylic acid as well as those agents that can be identified as antifungal agents using methods well known in the art.
Preferably, the antifungal agent of the present formulations is amphotericin (3 or fluconazole.
It is noted that a particular patient may possess a fungal organism acting as the etiological agent that is resistant to a particular antifungal agent. In such a case, an embodiment of this invention involves treating that patient with an effective antifungal agent (e.g., an antifungal agent that prevents the growth of, or kills, the fungal organism acting as the etiological agent). Such fungal organisms acting as etiological agents can be identified using collection and culture methods known in the art.
In one alternative embodiment, the formulation of the present invention may comprise any mount of antifungal agent that reduces, prevents, or eliminates one or more symptoms of, or associated with, fungus-induced rhinosinusitis without producing significant toxicity. In one embodiment, an effective amount rnay be any amount greater than or equal to th.e minimum inhibitory concentration (MIC) fox a fungal organism or isolate present within a particular individual's mucus that does not induce significant toxicity to the individual upon administration. Some antifungal agents may have a relatively large concentration range that is effective while others may have a relatively narrow effective concentration range. In addition, the effective amount can vary depending upon the specific fungal organism or isolate since certain organisms and isolates are more or less susceptible to particular antifungal agents. Such effective amounts can be determined for individual antifungal agents using commonly available or easily ascertainable information involving antifungal effectiveness concentrations, animal.
toxicity concentrations, and tissue permeability rates.
For example, non-toxic antifungal agents typically can be directly or indirectly administered in any amount that exhibits antifungal activity within mucus. In addition, antifungal agents that do riot permeate mucosal epithelium typically can be directly administered to the mucus in any amount that exhibits antifungal activity within mucus.
Using the information provided herein, such effective amounts also can be determined by routine experimentation in vitro or in vivo. For example, a patient having a fungus-induced rhinosinusitis can receive direct administration of an antifungal agent in an amount close to the MIC calculated from in vitro analysis. If the patient fails to respond, then the amount can be increased by, for example, ten fold. After receiving this higher .
concentration, the patient can be monitored for both responsiveness to the treatment and toxicity symptoms, and adjustrnents made accordingly.
In one embodiment, the present formulations comprise about O.OI ng to about 1000 mg per kg of body weight of the mammal per administration of formulation, where the formulation is administered directly to the nasal-paranasal mucose.
Antifungal agent particularly suitable for administration are itraconazole, ketoconazole, or voriconazole.
The MIC values for voriconazole range from about 0.003 µg/mL to about 4 :mu.glniL
depending upon the specific fungal organism or isolate tested. For fluconazole, the MIC
values range from about 0.25 µg/mL to greater than about 64 µglmL.
Various factors can influence the actual amount of antifungal agent in the formulations provided herein. For example, the frequency of administration of the formulations, duration of treatrnent, combination of other antifungal agents, site of administration, degree of inflammation, and the anatomical configuration of the treated area may require an increase or decrease in the actual amount of antifungal agent in the present formulations.
Table 1 sets forth preferable ranges and dosages of the antifungal agent of the presentinvention.
Table 1 Antifungal Agents and Dosages Brand PreferableMore Most Most Generic Class PreferablePreferablePreferable Name Name ~nge Ran a Ran a Dose Am hotericinFun Antifun0.5-150 4-30 m 7.5-IS 10 m 'zone al m m 12H
FluconazoleDiflucanAntifun0.5-150 20-70 25-50 10 m al m m m 12H
ltraconazoleS oranoxAntifun0.5-150 20-70 25-50 30 m al m m m 12H
Steroidal Anti-Inflarnmatory Steroidal anti-inflammatories for use herein include fluticasone, beclomethasone, any pharmaceutically acceptable derivative thereof, and any combination thereof. As used herein, a pharmaceutically acceptable derivative includes any salt, ester, enol ether, enol ester, acid, base, solvate or hydrate thereof. Such derivatives may be prepared by those of skill in the art using known methods for such derivatization.
In one alterative embodiment, the steroidal anti-inflammatory agents have a specific particle size distribution profile. As used herein, particle size refers to an average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art, such as, for examples sedimentation field flow fractionation, photon correlation spectroscopy, or disk centrifugation, among other techniques.
Fluticasone Preferably, the intranasal steroid of the present formulations is fluticasone propionate. Fluticasone propionate is a synthetic corticosteroid and has the empirical formula CZSH31F3~SS~ It has the chemical name S-(fluromethyl)6a,9-difluoro-11(3-17-dihydroxy 16a-methyl-3-oxoandrosta-1,4-diene-17~i-carbothioate,17-propionate.
Fluticasone propionate is a white to off white powder with a molecular weight of 500.6 and is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol.
In an embodiment, the formulations of the present invention may comprise a stervidal anti-inflammatory (e.g., fluticasone propionate) having the following particle size distribution profile: about 10% or less of the steroid particles have a particle size of less than 0.90 microns; about 25% or less of the steroid particles have a particle size of less than 1.6 microns; about 50% or less of the steroid particles have a particle size of less than 3.2 microns; about 75% or less of the steroid particles have a particle size of less than 6.10 microns; about 90% or less of the steroid particles have a particle size of less than 10 microns.
In an alternative embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory having the following particle size distribution profile; about 10% of the steroid particles have a particle size of less than 0.70 microns;
about 25% of the steroid particles have a particle size of less than 1.30 microns; about 50% of the steroid particles have a particle size of less than 2.5 microns; about 75% of the steroid particles have a particle size of less than 4.0 microns; about 90% of the steroid particles have a particle size of less than 6.0 microns; and greater than 90% or about 100% of the steroid particles have aparticle size of less than 10 microns. Preferably, the steroid is fluticasone propionate.
In one preferred embodiment, the formulation of the present invention comprises a steroid having the following particle size distribution profile: about 10%
of the steroid particles have a particle size less than 0.50 microns; about 25% of the steroid particles have a particle size less than 0.90 microns; about 50% of the steroid particles have a particle size less than 1.7 microns; about 75% of the steroid particles have a particle size less than 3.5 microns; about 90°l0 of the steroid particles have a particle size less than 5.5 microns.
In another alternative embodiment, greater than 90% or about 100% of the steroid particles have a particle size less than 15 microns, preferably less than 10 microns, more preferably less than 8 microns, most preferably less than 7 microns.
Beclomethasone Also preferably, the steroidal anti-inflammatory of the present formulations is beclomethasone dipropionate or its monohydrate. Beclomethasone dipropionate has the chemical name 9-chloro-llb,I7,21-trihydroxy 16b-methylpregna-1,4-diene-3,20-doine17,21-dipropionate. The compound may be a white~powder with a molecular weight of 521.25; and is very slightly soluble in water (Physicians' Desk Reference.RTl~, very soluble in chloroform, and freely soluble in acetone and in alcohol. ~ ' The formulations of the present invention may comprise a steroidal anti-inflammatory (e.g., beclometasone diproprionate) having the following particle size distribution profile: about 10% or less of the steroid particles have a particle size of less than 0.75 microns; about 25% or less of the steroid particles have a particle size of less than 1.5 microns; about 50% or less of the steroid particles have a particle size of less than 2.0 microns; about 75% or less of the steroid particles have a particle size of less than 3.5 microns; about 90% or less of the steroid particles have a particle size of less than 5.0 microns; and greater than 90% or about 100% of the steroid particles have a particle size of less than 10 microns.
In an alternative embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory having the following particle size distribution profile: about 10% of the steroid particles have a particle size of less than 0.35 microns;
about 25% of the steroid particles have a particle size of less than 0.70 microns; about 50% of the steroid particles have a particle size of less than 1.25 microns; about 75% of the steroid panicles have a particle size of less than 2.0 microns; about 90% of the steroid particles have a particle size of less than 3.0 microns; and greater than 90% or about 100% of the steroid particles have a particle size of less than 6.5 microns. Preferably, the steroid is beclomethasone dipropionate.
In one preferred embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory having the following particle size distribution profile: about 10% of the steroid particles have a particle size less than 0.40 microns;
about 25°/ of the steroid particles have a particle size less than 0.70 microns; about 50% of the steroid particles have a particle size less than 1.3 microns; about 75% of the steroid particles have a particle size less than 2.0 microns; about 90% of the steroid particles have a particle size less than 3.0 microns; greater than 90% or about 100% of the steroid particles have a particle size less than 6.O~microns.
In another alternative embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory having the following particle size distribution profile: about 10% of the steroid particles have a particle size less than 0.60 microns;
25% of the steroid particles have a particle size less than 0.90 microns;
about 50% of the steroid particles have a particle size less than 1.5 microns; about 75% of the steroid particles have a particle size less than 2.5 microns; about 90% of the steroid particles have a particle size less than 3.5 nucrons; greater than 90% or about 100% of the steroid particles have aparticle size~less than 6.0 microns.
In another alternative embodiment, greater than 90% or about 100% of the steroid particles have a particle size less than 15 microns, preferably less than 10 microns, more preferably less than 8 microns, most preferably less than 7 microns. In another preferred embodiment, greater than 90% or about 100% of the steroid particles have a particle size between 4 and 7 microns or 5 and 6 microns. In another embodiment, greater than 90% or about 100% of the steroid particles have a particle size less than 10 microns, preferably less than 7 microns; less than 6 microns; less than 5 microns, or less than 4 microns.
Providing steroidal anti-inflammatories according to the present invention is believed to be a more effective way to provide the medication to the nasal-paranasal region, thereby increasing bioavailability and efficacy of the steroid. It is understood that each of the particle size distribution profiles described in Serial Appl. Nos.
10/41,682 and lOl4I4,756 may be suitable for.any of the anti-inflammatory agents described herein.
The preferred anti-inflammatory agents are fluticasone and beclomethasone.
Also, the dosages described in these applications may also be suitable for use in the present invention. Each of these applications are incorporated herein by reference in their entirety.
Additionally, the formulations of the present invention may comprise fluticasone or beclomethasone alone or in combination with one or more other steroidal anti-inflammatories. Examples of steroidal anti=inflammatories for use herein include,'but are not limited to, betamethasone, triamcinolone, dexamethasone, prednisone, mometasone, flunisolide and budesonide. ' Other anti-inflammatory for use herein are listed below in Table 2.
Table 2 Steroidal Anti-inflammatory Agents and Dosages Most Most Preferable More PreferablePreferablePreferable Generic Brand NameClass Ran Ran a Ran a Dose Name a Ace 1c steineMucomist Mucol 125-S00 150-450 200-400 30D m Mucosil 'cs m m m 12H
Amikacin Amikin Aminoglycoside50-500 75-300 100-200 166 mg mg mg mg Q8-A hotericinFun izone Antifun 2.5-45 4-30 m 7.5-15 10 m 12H
H al m m Atro ine Anticoliner10-700 25-400 75-30 200 me 'c me me me 12H
Azelastine Astelin Antihistamine137-1096 204-822 382-616 411 mcg mcg mcg Q12H
me Azithro Zithromax Macrolide50-400 75-300 150-200 167 m in m m m 12H
Aztreonan Aaactam Monobactam250-1 300-900 475 750 450 m ODO m m 8H
m HeclamethasoneVanceril Steroidal0.1-4 0.2-3 0.2-2 0.8 mg Beclovent Anti- mg mg mg QI2H
inflammato HetamethasoneCelestone Steroidai0.1-4 0.2-3 0.2-2 0.8 mg . Anti- mg mg mg Q12H
inflammato Cefazolin Ancef, Cephlasporin250-1000 300-900 575-700 650 mg FCefzol mg mg mg Q8H
Gen Cefepine Maxipime Cephlasporin12S-1000 200-900 575-700 650 mg mg rng mg QI2H
Gen Cefonicid Moniacid Cephlasporin250-1000 300-900 575-700 600 mg mg mg mg Q24H
Gen CefaperazoneCefobid Cephlasporin250-1000 300-900 575-700 600 mg mg mg mg Q12H
Gen Cefotaxime Claforan Cephlasporin250-1000 300-900 575-700 600 mg mg mg mg Q8-Gen H ' 12H
Cefotetan Cefotan Cephlasporin250-1000 300-900 575-700 600 mg mg mg mg Q8-C ham 12H
cin Cefoxitin Mefoxiri Cephlasporin250-1000 300-900 575-700 600 mg ~ mg mg mg Q12H
-Ceoham cin CeRazidime Fortaz, Cephlasporin250-1000 300-900 475-750 550 mg Ceptaz mg mg mg Q12H
Gen II
CeflizoximeCeflzox Cephlasporin250.1000 300-900 575-?OD 600 mg mg mg mg Q8-Gen 12H
CeftriaxoneRocephin Cephtasporin250-1000 300-900 575-700 650 mg mg mg mg QI2H
Gen II
Cefuroxime Ceftin Cephlasporin100-600 200-520 250-400 285 mg mg mg mg Q8H
Gen II
Cephapirin Cefadyl Cephlasporin250-1000 300-900 575-700 650 mg mg mg mg Q12H
Gen Ci rofloxacinCi o uinolone25-200 50-175 75-110 90 m 12H
m m m Clind cin Cleocin Lincosamide50-600 75-500 125-300 225 m m rn m 12H
Cromolyn lntaIINasalcromMast 5-100 7.5-75 10-50 20 mg Sodium cell mg mg mg Q12H
.
stabilizer DexamethasoneDecadron Steroidal0.1-4 0.2-3 0.2-2 D.8 mg Anti- mg mg mg Q12H
inflammato Domase a1 Pulmo a Mucot 0.5-5 1-4. m 2-3 m 1.5 m ha 'c m 12H
Do c cline Vibra cin Tetrac 10-100 15-80 25-65 Z7 m 12H
cline m m m ErythromycinErythrocinMacrotide50-600 60-350 100-300 150 mg mg mg mg Q8H
Lactobionate FluconazoleDiflucan Antifun 12.5-150 20-70 25-50 30 m 12H
al m m m FlunisolideAerobid Steroidal0.1-4 0.2-3 0.2 2 0.8 mg Nasalide Anti- mg mg mg Q12H
inflammato FlurbiprofenOcofen Nonsteroidal0.01-2 0.05-I 0.1-0.S D.15 mg mg mg mg Q12H
Anti-inflammato FluticasoneFlonase Steroidal10-700 25-400 75-300 200 meg Anti- mcg mcg mcg Q24H
inflammato Gentam cin Garam cin Amino 10-200 30-150 80-120 95 m 8-12H
I oside m m m Ibuprofen Motrin Nonsteroidal25-400 30-300 50150 100 rng mg mg mg Q12H
Anti-inflammato I ratro Atrovent Anticholiner10 25-400 75-300 200 me ium 'c 700 mo me 12H
me ItraconazoleS oranox Antifungal12.5--I5020-70 mg 25-50 30 m 12H
m m Ketorolac Acular Nonsteroidal0.05-4 0.1-2 mg 0.3-I 0.5 mg mg mg QI2H
Anti-inflamatto LevofloxacinLeva uin uinolone40-200 50-150 60-80 70 m 12H
m rn m Linezolid Zyvox Miscellaneous50-600 7S-450 100-300 200 mg mg mg ng QI2H
anti-bacterial Loratidine Clarion Antihistamine0.5-10 1-7.5 m I-5 m 2 m 12H
m Mero enem Merrin Carba 200-75 250-700 300-500 33 m 8H
enem m m m~
MezlacillinMezlin Penicillin 300-1500375-1000 - 833 m m m ?50-950 H
m Miconazole Monistat Antifun 12.5-30030-200 50-100 60 m 12H
al m rii m MontelukastSin ulair Anoleukatriene 0.5-15 2-25 m 3-15 10 m 12H
m m Mu irocin Bactroban Antibacterial 1-25 1.5-20 2-15 10 m 6-8H
m m m Nafcillin Uni en Penicillin 250-1000300-900 575-700 600 m m m m 8H
Nedocromil Tilade Mast 1-25 3-IS mg 5-12 7 mg QI2H
cell rng mg stabilizer Ofloxacin Floxin uinolone 25-200 50-175 75-110 90 m 12H
m m m Oxacillin Prosta Penicillin Z50-1000300-900 575-700 600 m hin m m m 8H
OxymetazolinoAfiin Decongestant 0.05--0.50.075-0.4 0.1-0.3 0.2 mg mg mg QI2H
m Phen 1 herineNeo-S hineDecon 5-50 10-35 m 1S-20 10 m 12H
estant m m Pi eracillinPi racil Penicillin 100-1000125-750 250-600 460 m m m m H
Potassium Antis 30-20 40-150 50-80 60 m 12H
Iodide tic 0 m m m Rifa in ltifadin Miscellaneous _ 1000-4000 1500-35002250 m 500-5000m m 12H
m Taurolin TaurolidineNon 5-200 20-150 40-t20 80 mg antibiotic mg mg mg ' Q12H
antimicrobial Tetrah drozolidineTizine Decon 0.05-D.50.06-0.4 0.1-0.3 0.15 m estant m m m 12H
TicarcillinTimentin Penicillin 500-50001000-4000 1500-35002250 mg + mg mg mg Q6-Clavulanatc gH
Tobra cin Nebcin Aminooside10-200 30-150 80-120 95 m 812H
I m m m TriamcinaloneAsthmacor Steroidal 0.05-3 0.2-2.5 0.5-2 0.6 mg,Ql2H
Anti- mg mg mg Aristacortinflammato Vancomycin Vancocin Antibiotic- 50-400 75-325 125.250 166 mg mg mg mg Q6-8H
miscellaneous X lometazoline~ Otrivin Decon 0.05-0.40.075-03 0.1-0.Z 0125 m estant m m m 12H
ZafirlukastAccolate Antileukotriene 2-60 4-50 m 6-30 20 m 12H
m m Ant1b10tiC
The formulations of the present invention may further comprise an antibiotic.
Additionally, since more than one bacterial organism may be associated with the bacterial infection of the nasal-paranasal region, the present formulations may comprise a broad-spectrum antibiotic such as amoxycillin, erythromycin, or cefadroxil.
Alternatively, a combination of anti-bacterial agents with differing spectra of activity may also be used.
Examples of antibiotics for use in the present invention are shown in Table 3.
Antibiotic Agents and Dosages PreferableMare Most Most Generic Brand . Class gauge PreferablePreferablePreferable Flame Name Itan Ran a Dose a Anukacin Amikin amino 1 1-800 5-500 50-300 I50 m coside m m m SH
~ AzithromycinZithromaxMacrolide 25-400 ~ 75-300L150-200~ 167 ~ ~ ~ mg mg mg mg Q12H
AztreonanAzactam Monobactam150-1000300-900 475-750 450 m CefazolinAncef, Cephlasporinm m m 8H
Kefzol (Gen 150-1000300-900 575-700 650 mg Cefepine I mg mg mg QSH
Maxipime Cephlasporin Cefonicid (Gen 75-1000 200-900 575-?00 650 mg Moniacid IV mg mg mg Q12H
Cefaperazone Cephlasporin Cefobid (Gen 150-1000300-900 575-700 600 mg I mg mg mg Q24H
Cephlasporin (Gen 150-1000300-900 575-700 600 mg ItI mg mg mg Q12H
CefotaximeClaforan Cephlasporin150-1000300-900 575-700 600 mg (Gen mg mg mg Q8-IlI I2H
CefotetanCefotetanCephlasporin150-1000300-900 575-700 600 mg mg mg mg Q8-C ha cin I2H
CefoxitinMefoxia' Cephlasporin150-1000300-900 575-700 600 mg mg mg mg Q12H
C h in Ceftazidime1ortaz, Cephlasporin150-1000300-900 475-750 550 mg Ceptaz (Gen mg mg mg Q12H
CeftizoximeCeBzox Cephiasporin150-1000300-900 575-700 600 mg . (Gen mg mg mg , Q8-CeflriaxoneRocephin Cephlasporin150-1000300-900 575-700 650 mg (Gen mg mg mg Qt2H
n CefuroximeCeftin Cephlasporin50-600 200-520 250-400 285 mg (Gen mg mg mg Q8H
I
CephapirinCefadyl Cephlasporin150-1000300-900 575-700 650 mg (Gen mg mg mg Qt2H
I
Ci rotloxacinCi ro uinolone 15-200 50-175 750110 90 m m m m 12H
Clinda Cleocin Lincosamide25-600 75-500 125-300 225 m cin m m m . 12H
Do line Vibra Tetrac 10-100 15-80 25-65 27 m cin cline m m m 12H
ErythromycinErythtocinMacrolide25-600 60-350 100-300 I50 mg mg mg mg Q8H
Lactobionate GentamicinGaram Amino I-80D 5-500 50-300 150 m cin 1 oside m m m 8H
Kana cin ICantrex Amino 1-800 5-500 50-300 150 m 1 oside m m m 8H
LinezotidZyvox Miscellaneous25-600 75-450 100-300 200 mg mg mg ng Q12H
anti-bacterial MealocillinMezlin Penicillin10D-1500375-1000 750-950 833 m ~ m m m H
M irocin BactrobanAntibacterial1-25 1.520 2-15 10 m m m m d-8H
NafcillinUni en Penicillin150-1000300-900 575-700 600 m m m m 8H
NetilmicinNetro Amino I-800 5-500 50-300 i50 m cin 1 oside m m m 8H
Neom cin M cifradinAmino 1-800 5-500 50-300 I50 m 1 oside m m m SH
OxacillinProsta Penicillin150-1000300-900 575-700 600 m hin m m m 8H
Paromo Humatin Amino I-800 5-500 50-300 150 m cin 1 oside m m m 8H
Pi eracillinPi cil Penicillin50-1000 125-750 250600 460 m m m m H
S to cin Amino 1-800 5-500 50-300 150 m 1 oside m m m 8H
TicarcillinTimentin Penicillin200-50001000-40001500-35002250 + mg mg mg mg Q6-Clawlanaic 8H
Tobra Amino 1-800 5-500 50-300 150 m cin 1 coside m m m 8H
VancomycinVancocin Antibiotic-25-400 75-325 125.250 166 mg mg mg mg Q6-8H
miscellaneous Antiviral Agents The formulations of the present invention may comprise a therapeutically effective amount of one or more antiviral agents. These agents can be administered individually or simultaneously with the steroidal agent of the present invention. The antiviral agent may also include Acyclovir, Famciclovir, Valacyclovir, edoxudine, ganciclovir, foscarnet, cidovir (vistide), Vitl-asert, Formivirsen, HPMPA (9-(3 hydroxy-2-phosphonomethoxypropyl)adenine), PMEA (9-(2-phosphonomethoxyethyl)adenine), IiPMPG (9-(3-Hydroxy-2-(Phosphonomethoxy)propyl)guanine), PMEG (9-[2-(phosphonomethoxy)ethyl]guanine), HPMPC (1-(2-phosphonomethoxy-3-hydroxypropyl)-cytosine), ribavirin, EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamine), pyrazofurin (3-[beta-D-ribofuranosyl]-4-hydroxypyrazole-5-carboxamine), 3-Deazaguanine, GR-92938X (1-beta-D-ribofuranosylpyrazole-3,4-dicarboxamide), LY253963 (1,3,4-thiadiazol-2-yl-cyanamide), RD3-0028 (1,4-dihydro-2,3-Benzodithiin), CL387626 (4,4'-bis[4,6-di[3-aminophenyl-N,N-bis(2-carbamoylethyl)-sulfonilimino]-1,3,5-triazin-2-ylamino-biphenyl-2,2'-disulfonic acid disodium salt), BABIM (Bis[5-Amidino-2-benzimidazolyl]methane), and N1H351.
Other suitable dosages and methods of treatment of the ingredients described herein are described in US 2001/0006944AI, pub. date July 5, 2001, which is incorporated herein by reference in its entirety. .
Other Components The formulation of the present invention may be in any form piovided the formulation can be administered to a mammal in an amount, at a frequency, and for a duration effective to prevent, reduce, or eliminate one or more symptoms associated with Rhinosinusitis, including fungus induced Rhinosinusitis. For example, a formulation within the scope of the invention can be in the form of a solid, liquid, and/or aerosol including, without limitation, powders, crystalline substances, gels pastes, ointments, salves, creams, solutions, suspensions, partial liquids, sprays, nebulae, mists, atomized vapors, tinctures, pills, capsules, tablets, and gelcaps. In addition, the formulation can contain a cocktail of other ingredients, particularly those described herein.
For example, a formulation within the scope of the invention can contain, without limitation, one, two, three, four, five, or more different antifungal agents, antibiotics, antiviral agents, or the other ingredients described herein. Further, formulations within the scope of the invention can contain additional ingredients including, without limitation, pharmaceutically acceptable aqueous vehicles, pharmaceutically acceptable solid vehicles, steroids, mucolytic agents, antibacterial agents,.anti-inflammatory agents, immunosuppressants, dilators, vaso-constrictors, decongestants, leukotriene inhibitors, anti-cholinergics, anti-histamines, therapeutic compounds and combinations thereof.
Such antiviral agents may include IIVIPDH inhibitors, inhibitors of virus adsorption entry, inhibitors of fusion with host cells, antisense oligonucleotides, and nucleoside analogues.
In one embodiment, the present formulations may be provided in any form suitable for intranasal administration. In another alternative embodiment, the formulations of the present invention are in solution or suspension form suitable for intranasal administration.
In an embodiment, the formulation of the present invention may comprise a preservative, suspending agent, wetting agent, tonicity agent andlor diluent.
In one embodiment, the formulations provided herein may comprise from about 0.01 % to about 95%, or about 0.01 % to about 50%, or about 0.01 % to about 25%, or about 0.01 % to about 10%, or about 0.01% to about 5% of one or more pharmacologically suitable suspending fluids which is physiologically acceptable upon administration.
Pharmacologically suitable fluids for use herein include, but are not limited to, polar solvents, including, but not limited to, compounds that contain hydroxyl groups or other polar groups. Solvents include, but are not limited to,. water or alcohols, such as ethanol, isopropanol, and glycols including propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol and polyoxyethylene alcohols. Polar solvents also include protic solvents, including, but not limited to, water, aqueous saline solutions with one or more pharmaceutically acceptable salt(s), alcohols, glycols or a mixture there of. In one alternative embodiment, the water for use in the present formulations should meet or exceed the applicable regulatory requirements for use in drugs.
In certain embodiments herein, the formulations of the present invention have a pH of about 2.0 to about 9Ø Optionally, the formulations of the present invention may contain a pH buffer. For example, a buffer may comprise any known pharmacologically suitable buffexs which are physiologically acceptable upon administration intranasally.
The buffer may be added to maintain the pH of the formulation between about 3.0 and about 7.0, for example.
Sterility or adequate antimicrobial preservation may be provided as part of the present formulations. Since certain formulations of the present invention are intended to be administered intranasally, it is preferred that they be free of pathogenic organisms. 'A
benefit of a sterile liquid suspension is that it reduces the possibility of introducing contaminants into the individual when the suspension formulation is administered intranasally, thereby reducing the chance of an opportunistic infection.
Processes which may be considered for achieving sterility may include any appropriate sterilization steps known in the art.
In one embodiment, the formulation of the present invention is produced under sterile conditions, and the micronization of the steroidal anti-inflammatory is performed in a sterile environment, and the mixing and packaging is conducted under sterile .
conditions. In one alternative embodiment, one or more ingredients in the present formulation may be sterilized by steam, gamma radiation or prepared using or mixing sterile steroidal powder and other sterile ingredients where appropriate.
Also, the formulations may be prepared and handled under sterile conditions, or may be sterilized before or after packaging.
In addition to or in lieu of sterilization, the formulations of the present invention may contain a pharmaceutically acceptable preservative to minimize the possibility of microbial contamination. Additionally, a pharmaceutically-acceptable preservative may be used in the present formulations to increase the stability of the formulations. It should be noted, however, that any preservative must be chosen for safety, as the treated tissues may be sensitive to irntants. Preservatives suitable for use herein include, but are not limited to, those that protect the solution from contamination with pathogenic particles, including phenylethyl alcohol, benzalkonium chloride, benzoic acid, or benzoates such as sodium benzoate. Preferably, the preservative for use in the present formulations is benzalkonium chloride or phenylethyl alcohol: In certain embodiments, the formulations herein comprise from about 0.01% and about 1.0% w/w of benzalkonium chloride, or from about 0.01% and about 1% v/w phenylethyl alcohol. Preserving agents may also be present in an amount from about 0.01% to about 1%, preferably about 0.002% to about 0.02% by total weight or volume of the formulation.
The formulations provided herein may also comprise from about 0.01 % to about 90%, or about 0.01% to about 50%, or about 0.01% to about 25%, or about 0.01%
to about 10%, or about 0.01 % to about 1 % w/w of one or more emulsifying agent, wetting agent or suspending agent. Such agents for use.herein include, but are not limited to, polyoxyethylene sorbitan fatty esters or polysorbates, including, but not limited to, polyethylene sorbitan monooleate (Polysorbate 80), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 65 (polyoxyethylene (20) sorbitan tristearate), polyoxyethylene (20) sorbitan mono-oleate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate; lecithins; algiiiic acid;
sodium alginate; potassium alginate; ammonium alginate; calcium alginate;
propane-1,2-diol alginate; agar; carrageenan; locust bean gum; guar gum; tragacanth;
acacia; xanthan gum; karaya gum; pectin; amidated pectin; ammonium phosphatides;
microcrystalline cellulose; methylcellulose; hydroxypropylcellulose;
hydroxypropylmethylcellulose;
ethylmethylcellulose; carboxymethylcellulose; sodium, potassium and calcium salts of fatty acids; mono-and di-glycerides of fatty acids; acetic acid esters of mono-and di-glycerides of fatty acids; lactic acid esters of mono-and di-glycerides of fatty acids; citric acid esters of mono-and di-glycerides of fatty acids; tartaric acid esters of mono-and di-glycerides of fatty acids; mono-and diacetyltartaric acid esters of mono-and di-glycerides of fatty acids; mixed acetic and tartaric acid esters of mono-and di-glycerides of fatty acids; sucrose esters of fatty acids; sucroglycerides; polyglycerol esters of fatty acids;
polyglycerol esters of polycondensed fatty acids of castor oil; propane-1,2-diol esters of fatty acids; sodium stearoyl-2lactylate; calcium stearoyl-2-lactylate;
stearoyl tartrate;
sorbitan monostearate; sorbitan tristearate; sorbitan monolaurate; sorbitan monooleate;
sorbitan monopalinitate; extract of quillaia; polyglycerol esters of dimerised fatty acids of Soya bean oil; oxidatively polymerised soya bean oil; and pectin extract. Tn certain embodiments herein, the present formulations comprise polysorbate 80, microcrystalline cellulose, carboxymethylcellulose sodium and/or dextrose.
The present formulations may further comprise from about 0.01% to about 90%, or about 0.01% to about 50%, or about 0.01% to about 25%, or about 0.01% to about 10%, or about 0.01% to about 1% wlw of one or more excipients and additives which are pharmacologically suitable. Excipients and additives generally have no pharmacological activity, or at least no undesirable pharmacological activity. The concentration of these may vary with the selected agent, although the presence or absence of these agents, or their concentration is not an essential feature of the invention. The excipients and additives may include, but are not limited to, surfactants, moisturizers, stabilizers, complexing agents, antioxidants, or other additives known in the art.
Complexing agents include, but are not limited to, ethylenediaminetetraacetic acid (EDTA) or a salt thereof, such as the disodium salt, citric acid, nitrilotriacetic acid and the'salts thereof. In another embodiment, particularly in the suspension formulations provided herein, the cornplexing agent is sodium edetate. In one embodiment, the compositions contain sodium edetate at a concentration of about 0.05 mg/mL to about 0.5 mg/mL, or about 0.1 mg/mL to about 0.2 mg/mL. Also, for example, the formulations of the present invention may comprise from about 0.001% to about 5% by weight of a humectant to inhibit drying of the mucous membrane and to prevent irntation. Any of a variety of pharmaceutically acceptable humectants can be employed, including sorbitol, propylene glycol, polyethylene glycol, glycerol or mixtures thereof, far example.
The formulations provided herein also may comprise about 0.01% to about 90%, or about 0.01% to about 50%, or about 0.01% to about 25%, or about 0.01% to about 10%, or about 0.01 % to about 10% w/w of one or more solvents or co-solvents to increase the solubility of any of the components of the present formulations.
Solvents or co-solvents for use herein include, but are not limited to, hydroxylated solvents or other pharmaceutically- acceptable polar solvents, such as alcohols including isopropyl alcohol, glycols such as propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, and polyoxyethylene alcohols. In another embodiment, the formulations of the present invention may comprise one or more conventional diluents known in the art. The preferred diluent is purified water.
Tonicity agents may include, but are not limited to, sodium chloride, potassium chloride, zinc chloride, calcium chloride and mixtures thereof. Other osmotic.adjusting agents may also include, but are not limited to, mannitol, glycerol, and dextrose or mixtures thereof. In an alternative embodiment, the present formulation may comprise about 0.01% to about 10% w/w, or about 1% to about 8% w/w, or 1% to about 6%
w/w, preferably about 5.0% wlw. The preferred tonicity agent is anhydrous dextrose.
In one alternative embodiment, the formulations of the present invention are stable. As used herein, the stability of formulations provided herein refers to the length of time at a given temperature that greater than 80%, 85%, 90% or 95% of the initial amount of the active ingredients is present in the formulation. For example, the formulations provided herein may be stored between about 15°C and about 30°C, and remain stable for at least 1, 2, 12,18, 24 or 36 months. Also, the formulations may be suitable for administration to a subject in need thereof after storage for more than 1, 2, 12,18, 24 or 36 months at 25°. Also, in another alternative embodiment, using Arrhenius Kinetics, more than 80%, or more than 85%, or more than 90%, or more than 95%
of the initial amount of active ingredients remains after storage of the formulations for more than 1, 2,12, 18, 24 or 36 months between about 15°C and about 30°C.
The formulations of the present invention may be manufactured in any conventional manner known in the art, or by minor modification of such means.
For example, the formulations may be manufactured by thoroughly mixing the ingredients described herein at ambient or elevated temperatures in order to achieve solubility of ingredients where,appropriate.
The preparation of the steroidal inflammatory of the present invention, e.g., fluticasone propionate and beclomethasone dipropionate, having a specific particle size distribution profile may be obtained by any conventional means lmown in the art, or by minor modification of such means. For example, suspensions of drug particles can rapidly undergo particulate size reduction when subj ected to "j et milling"
(high pressure particle in liquid milling) techniques. Other known methods for reducing particle size into the micrometer range include mechanical milling, the application of ultrasonic energy and other techniques.
In addition, the formulations of the present invention may comprise any of the following components: (r) antihistamine: (ii) non-steroidal anti-flarnmatories; (iii) decongestants; (iv) mucolytics; (v) anticholinergics; or (vi) mass cell stabilizers.
Examples of such components are found in U.S. 2002/0061281 Al, published May 23, 2002., This reference is incorporated herein by reference in its entirety.
In one alternative embodiment, the present~invention is directed to a pharmaceutical composition that may be useful in treating rhinosinusitis caused by Alpha Hemolytic Sreptococci, Beta Hemolytic Streptococci, Branhamella Catarrhalis, Diptheroids, Heaemophilis influenza (beta-lactamase positive and negative), Moraxella species, Psuedomonas aeroguinosa, Pseudomas maltophilia, Serratia marcesns, Staphylococcus aureus, Streptococcus pheumonia, Aspergillosis, Mucor and Candida albicans, Flusarium, Curvularia, crytococcus, coccidiodes, and histoplasma.
Mode of Administration Administration of the present formulations can be any type of administration that places the present formulations in contact with nasal-paranasal mucosa. Direct intranasal administration includes, without. limitation, nasal irrigations, nasal sprays, nasal inhalations, and nasal packs with, for example, saturated gauze provided the administered agent contacts nasal-paranasal mucosa prior to crossing epithelium. In addition, injections into the nasal-paranasal cavities using, for example, a needle or catheter tube is considered a direct intranasal administration provided the administered agent contacts nasal-paranasal mucosa after leaving the needle or catheter tube and prior to crossing epithelium. Any device can be used to directly administer the present formulations intranasally including, without limitation, a syringe, bulb,, inhaler, canister, spray can, nebulizer, and mask.
Indirect administration to the nasal-paranasal anatomies can include, without limitation, oral, intravenous, intradermal, and intraperitoneal administrations provided the administered agent contacts nasal-paranasal mucosa. In addition, any device can be used to indirectly administer an agent to the nasal-paranasal anatomy including, without limitation, a syringe and regulated release capsule.
The present formulations may be packaged in any conventional manner suitable for administration of the present formulations. Spray administration containers for various types of nasal formulations have been known in the past and substantially all will be equally suitable for the present formulations, provided that the container materials is compatible with the formulation. In an embodiment, the formulation of the present invention herein is packaged in a container such that it can be dispersed as a mist to be directed into each nostril. For. example, the container may be made of flexible plastic such that squeezing the bottle's sides impels the spray out through the nozzle into the nasal cavity. Alternatively, a small pump button may pump air into the container and cause the liquid spray to be emitted on the return stroke when pressed.
In an alternative embodiment, the formulations of the present invention are packaged in a container pressurized with a gas which is inert to the user and to the ingredients of the solution. The gas may be dissolved under pressure in the container or may be generated by dissolution or reaction of a solid material which forms the gas as a product of dissolution or as a reaction product. Suitable inert gases which can be used herein include nitrogen, argon, and carbon dioxide. Also, the formulations herein may be administered as a spray or aerosol wherein the formulation is packaged in a pressurized container with a liquid propellant such as dicholorodifluoro methane or chlorotrifluoro ethylene, or other propellant. .
Preferably, the present formulations are packaged in a metered dose spray pump, or metering atomizing pump, such that each actuation of the pump delivers a fixed volume of the formulation (i.e. per spray-unit). For administration in drop or other topical form, the formulations herein may suitably be packaged in~a container provided with a conventional dropperlclosure device, comprising a pipette or the like, preferably delivering a substantially fixed volume of the formulation.
Method of Treatment The present invention is also directed to a method for treating rhinosinusitis, including fungus-induced rhinosinusitis. In one embodiment, the method of treating rhinosinusitis of the present invention comprises the step of administering a therapeutically effective amount of the formulation of the present invention to a mammal in need thereof. The formulation may comprise the steroidal agent of the present invention alone or in combination with an anti-fungal agent, an antibiotic or antiviral agent. The formulation is preferably administered intranasally. In one embodiment, the formulation is administered directly to the nasal-paranasal mucosa. In an alternative embodiment, the formulation is administered intranasally via a metered dose spray.pump.
In general, the course of treatment for any individual with respect to any of the active ingredients described herein can be readily determined by his or her physician.
The method of the present invention may further comprise administering the formulation of the present for a duration or frequency sufficient to treat one or more symptoms of rhinosinusitis, including fungus-induced rhinosinusitis. For example, the formulation may be administered one time to about 10 times a day for about one day.to about 100 days or more, or until such fungus-induced rhinosinusitis is treated. In an embodiment, the method of the present invention comprises administering to a mammal diagnosed with fungus-induced rhinosinusitis a formulation comprising a therapeutically effective amount of an antifungal agent and a steroidal anti-inflammatory intranasally via a metered dose spray pump one to three times a day for up to two weeks. In an alternative embodiment, the administration of the present formulations may comprise 1, 2, 3, 4, 5, 6, 7 or 8 applications of the present fornnulativn to the nasal-paranasal mucosa one, two, three, four or five times a day.
In an alternative embodiment, the formulation of the method of the present invention further comprises an antibiotic. However, when administering antibiotics, physicians must keep in mind the incidence of drug-resistant bacteria in their community and consider the patient's overall health status. Special attention should be given to diseases that could impede normal recovery from infection and/or predispose to complications (e.g., diabetes mellitus, chronic pulmonary disease, asthma, cystic fibrosis and immune deficiencies). Additionally, physicians should consider whether or not the patient is immunocomprimised in selecting an antibiotic. In one embodiment, the antibiotic is administered for a period of 1 day to about 10 weeks. Iwan alternative embodiment, the antibiotic is administered for about .1 day to about 28 days.
Accordingly, the present invention provides a method of treating fungus-induced rhinosiriusitis associated with a bacterial infection in the nasal paranasal region, comprising the steps of administering a formulation comprising an antifungal agent, steroidal anti-inflammatory, and antibiotic until said bacterial infection is cured, and then administering a formulation comprising an antifungal agent and steroidal anti-.
inflammatory.
In an alternative embodiment, the present invention provides a method of treating fungus-induced rhinosinusitis, comprising the steps of administering a formulation comprising a steroidal anti-inflammatory alone or in combination or in conjunction with an antifungal agent, antibiotic or antiviral agent. For example, the steroidal agent may be administered separately from the antif-.ungal agent ox antibiotic, or each ingredient can be administered simultaneously (e.g., in a single formulation) concurrently, subsequently, or in tandem. In another embodiment, each ingredient is administered individually in its own formulation and pursuant to an appropriate dosage regimen for that particular ingredient. Suitable dosage regimens for steroidal agents, fungal agents, antibiotics or antiviral agents are known by those skilled in the art.
V. EXAMPLES
Examples 1-5 herein are prophetic examples provided to illustrate, but riot to limit, the formulations and methods of the present invention. They are presented with the understanding that changes can be and may need to be made to a specific composition in order to obtain or optimize the formulation. Such modifications to the following prophetic examples, if needed, are normal and understandable to those of ordinary skill in the art, and shall not be used to limit the invention.
It is believed that prophetic examples 1-5 would be suitable for administration to the nasal-paranasal mucosa of an individual suffering from fungus-induced rhinosinusitis associated with a bacterial infection. The formulations may be sterile. It is understood that the steroid, antibiotic, antifungal agent or the other ingredients described herein may be administered in the same formulation, or may be administered individually, or in any combination thereof.
Example 1 Am hotericin B 2.0 -100.0 m ml Neom cin Sulfate 5.0 -100.0 m ml Phen leth 1 Alcohol 0.5 -10.0 m .ml Fluticasone Pro innate 0.25 -1.0 m mI
Microc stalline Cellulose S.0 -15.0 m ml ' Pol orbate 80 0.1-1.0 mg/ml Purified Water - q.s.
Example 1 is a prophetic example of a formulation of the present invention, wherein about 10% of the fluticasone propionate particles have a particle size of less than 0.70 microns; about 25% of the fluticasone propionate particles have a particle size of less than 1.30 microns; about 50% of the fluticasone propionate particles have a particle size of less than 2.5 microns; about 75% of the fluticasone propionate particles have a particle size of less than 4.0 microns; about 90% of the fluticasone propionate particles have a particle size of less than 6.0 microns; and greater than 90% or about 100% of the fluticasone propionate particles have a particle size of less than 10 microns. The solution of Example 1 may be made by methods known to those of ordinary skill in the art.
Example 2 Fluconazole _ _ 1.0 - 20.0 m ml Neomycin Sulfate 5.0 -100.0 m ml Phen leth 1 Alcohol 0.5 -10.0 m ml Fluticasone Pro innate 0.25 -1.0 m ml Microcrystalline Cellulose5.0 -15.0 mg/ml Pol sorbate 80 0.1-1.0 m ml Purified Water .s.
Example 2 is a prophetic example of a formulation of the present invention, wherein about 10% of the fluticasone propionate particles have a particle size of less than 0.70 microns; about 25% of the fluticasone propionate particles have a particle size of less than 1.30 microns; about 50% of the fluticasone propionate particles have a particle size of less than 2.5 microns; about 75% of the fluticasone propionate particles have a .
particle size of less than 4.0 microns; about 90% of the fluticasone propionate particles have a particle size of less than 6.0 microns; and greater than 90% or about 100% of the fluticasone propionate particles have a particle size of less than 10 microns.
The solution of Example 2 may be made by methods known to those of ordinary skill in the art.
Example 3 Am hotericin B 2.0 -100.0 m ml Neom cin Sulfate 5.0 -100.0 m ml Benzalkonium Chloride 0.1- 0.5 rn ml Dextrose 20.0 -100.0 Phen ' leth 1 Alcohol 0.5 -10.0 m .ml Beclomethasone Di ro 0.25 -1.0 m ml innate Purified Water .s.
Example 3 is a prophetic example of a formulation of the present invention, wherein about 10% of the beclomethasone dipropionate particles have a particle size less than 0.40 nucrons; about 25% of the beclomethasone dipropionate particles have a .
particle size less than 0.'70 microns; about 50% of the beclomethasone dipropionate particles have a particle size less than 1.3 microns; about 75% of the beclomethasone dipropionate particles have a particle size less than 2.0 microns; about 90%
of the beclomethasone dipropionate particles have a particle size less than 3.0 microns; and greater than 90% or about 100% of the beclomethasone dipropionate particles have a particle size less than 6.0 microns. Example 3 may be made by methods known to those of ordinary skill in the art.
Example 4 Fluconazole 1.0 - 20.0 m ml Neom cin Sulfate 5.0 -100.0 m ml Benzalkonium Chlaride 0.1- 0.5 m ml ' Dextrose '20.0 -100.0 Phen leth 1 Alcohol 0.5 -10.0 m .ml Beclomethasone Di ro 0.25 -1.0 m ml innate Purified Water .s.
Example 4 is a prophetic example of a formulation of the present invention, wherein about 10% of the beclomethasone dipropionate particles have a particle size less than 0.40 microns; about 25% of the beclomethasone dipropionate particles have a particle size less than 0.70 microns; about 50% of the beclomethasone dipropionate particles have a particle size less than 1.3 microns; about 75% of the beclomethasone dipropionate particles have a particle size Iess than 2.0 microns; about 90%
of the beclomethasone dipropionate particles have a particle size less than 3.0 microns; and greater than 90% or about I00% of the beclomethasone dipropionate particles have a particle size less than 6.0 microns. Example 4 may be made by methods known to those of ordinary skill in the art.
Example 5 Fluconazole . 1.0 - 20.0 m /m1 Benzalkonium Chloride 0.1- 0.5 m ml Dextrose 20.0 -100.0 Phen leth 1 Alcohol 0.5 -10.0 m .ml Beclomethasone Di ro 0.25 -1.0 mg/m1 innate Purified Water .s.
Example 5 is a prophetic example of a formulation of the present invention, wherein about 10% of the beclomethasone dipropionate particles have a particle size less than 0.40 microns; about 25% of the beciomethasone dipropionate particles have a particle size less than 0.70 microns; about 50% of the beclomethasone dipropionate particles have a particle size less than 1.3 microns; about 75% of the becloriiethasone dipropionate particles have a particle size less than 2.0 microns; about 90%
of the beclomethasone dipropionate particles have a particle size less than 3.0 microns; and greater than 90% or about 100% of the beclomethasone dipropionate particles have a particle size less than 6.0 microns. Example 5 may be made by methods known to those of ordinary skill in the art.
The Examples herein are presented for illustrative purposes only. They are not intended to limit the scope of the invention. Further, it should be understood that various changes and modifications to the embodiment described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims. Also, the invention may suitably comprise, consist of or consist essentially of the elements or steps described herein. Further, the invention described herein suitably may comprise or be practiced in the absence of any element or step which is not specifically disclosed herein. Further, one or more step described herein may be performed simultaneously with another step.
In many instances the fungus-induced rhinosinusitis may be accompanied by, or associated with, a bacterial infection of the nasal-paranasal mucosa. In one embodiment, the fonnulations of the present invention comprise an antibiotic. In an alternative embodiment, the present formulations comprise about 1 to about 800 mg of the antibiotic neomycin sulfate.
The formulations of the present invention may be provided in any form which directly contacts the formulation with the nasal-paranasal mucosa. In one embodiment, the present formulation is provided as a sterile aqueous solution or.
suspension. In an alternative embodiments the formulation is in a metered dose spray pump.
The.present invention also generally relates to methods for treating rhinosinusitis, including fungus-induced rhinosinusitis. In one alternative embodiment, an individual suffering from rhinosinusitis may be administered a steroidal agent of the, present invention alone, or in combination or conjunction with an anti-fungal agent, antibiotic or antiviral agent. For example, the steroidal agent may be administered separately from the anti-fungal agent or antibiotic, or each of these ingredients may be administered simultaneously (e.g., in a single formulation) or individually, concurrently, in tandem or subsequently relative to each other, or in any combination thereof.
Y. DETAILED DISCUSSION OF THE IIVYENTION
The present invention is directed to formulations for the treatment of one or more symptoms of rhinosinusitis in an individual, lZhinosinusitis occurs in the nasal paranasal region. Symptoms of rhinosinusitis include, without limitation, facial pain, pressure, and/or fullness; loss of smell; nasal obstruction or blockage; nasal or postnasal discharge;
rhinorrhea; hyposimia/ansomnia; fever; headaches; halitosis; fatigue; dental pain; cough;
and ear pain, pressure, and/or fullness. Upon examination, the presence of thick mucus or the visual identification of nasal or paranasal obstruction with mucus or polyps often indicates a rhinosinusitis condition.
Nasal polyps may also be associated with or indicative of rhinosinusitis.
Nasal polyps are outgrowths from the nasal-paranasal mucosa that are typically smooth, gelatinous, semitranslucent, round or pear shaped, and pale. In general, nasal polyps are located on the lateral wall of the nose, usually in the middle meatus or along the middle and superior tuxbinates. Most nasal polyps arise from the ethmoid sinus but some polyps originate in the maxillary sphenoid sinuses. The mass of a nasal.polyp is composed mainly of edematous fluid with sparse fibrous cells and a few mucous glands.
The surface epithelium of nasal and paranasal polyps generally reveals squamous metaplasia.
Eosinophils are usually present in polyps in moderate to large numbers, and it is now known that nasal polyp fluid contains greater than normal concentrations of IgA, IgE, IgG, and IgM antibodies as well as abnormally high concentrations of IL-5, a cytokine that contributes to eosinophil activation and survival.
It is understood that the scope of the invention is directed to the treatment of rhinosinusitis including, but.not limited to, any rhinosinusitis condition, including, but not limited to, acute, subacute, recurrent acute and chronic rhinosinusitis, which may be accompanied by, aggravated by, associated with or caused by (in whole or in part) fungi, viruses, or microorganisms in the mucosa. For example, rhinosinusitis may include fungus-induced rhinosinusitis caused by, for example, an immunologic response to mucosal fungi or other organism. In one alternative enibodiment, the fungus-induced rhinosinusitis is allergic fungal rhinosinusitis, or AFS.
Formulation In one alternative embodiment, the present invention is directed to formulations for the treatment of rhinosinusitis. In one embodiment, the formulations comprise a steroidal anti-inflammatory, alone or in combination with an antifungal agent, antibiotic or antiviral~ agent. As used herein, treatment means the prophylaxis, prevention or amelioration of one or more symptoms of, or associated with, rhinosinusitis, or any manner in which one or more of the symptoms of, or associated with, rhinosinusitis are beneficially altered or are prevented from worsening. . As used herein, amelioration means any lessening, whether permanent or temporary, lasting or transient, of one or more symptoms of rhinosinusitis, including but not limited to fungus-induced rhinosinusitis.
Antifun~al Aeent Antifungal agents for use herein include any agent effective in treating rhinosinusitis, including fungus-induced rhinosinusitis. Preferably, the antifungal agent of the present formulations reduces the presence of fungal organisms within mucus to a level such that the characteristic inflammatory responses and resulting damages associated with fungal induced rhinosinusitis are lessened, whether permanent or temporary, lasting or transient, stopped, treated, or prevented.
For example, in one alternative embodiment of the present invention, an antifungal agent for. use herein may include any agent that prevents the growth of or kills a fungal organism such as antifungal polyene macrolides, tetraene macrolides, pentaenic macrolides, fluorinated pyrimidines, imidazoles, triazoles, azoles, halogenated phenolic ethers, thiocarbamates, and allylamines, and other. In addition, antifungal agents can be agents that interpolate fungal cell wall components or act as sterol inhibitors. Specific antifungal agents within the scope of the invention include, without limitation, amphotericin Vii, flucytosine, ketoconazole, miconazole, itraconazole, fluconazole, griseofulvin, clotrimazole, econazole, terconazole, butoconazole, oxiconazole, sulconazole, saperconazole, voricona2ole, ciclopirox olamine, haloprogin, tolnaftate, naftifine, nystatin, natamycin, terbinafine hydrochloride, morpholines, butenafine undecylenic acid, Whitefield's ointment, propionic acid, and caprylic acid as well as those agents that can be identified as antifungal agents using methods well known in the art.
Preferably, the antifungal agent of the present formulations is amphotericin (3 or fluconazole.
It is noted that a particular patient may possess a fungal organism acting as the etiological agent that is resistant to a particular antifungal agent. In such a case, an embodiment of this invention involves treating that patient with an effective antifungal agent (e.g., an antifungal agent that prevents the growth of, or kills, the fungal organism acting as the etiological agent). Such fungal organisms acting as etiological agents can be identified using collection and culture methods known in the art.
In one alternative embodiment, the formulation of the present invention may comprise any mount of antifungal agent that reduces, prevents, or eliminates one or more symptoms of, or associated with, fungus-induced rhinosinusitis without producing significant toxicity. In one embodiment, an effective amount rnay be any amount greater than or equal to th.e minimum inhibitory concentration (MIC) fox a fungal organism or isolate present within a particular individual's mucus that does not induce significant toxicity to the individual upon administration. Some antifungal agents may have a relatively large concentration range that is effective while others may have a relatively narrow effective concentration range. In addition, the effective amount can vary depending upon the specific fungal organism or isolate since certain organisms and isolates are more or less susceptible to particular antifungal agents. Such effective amounts can be determined for individual antifungal agents using commonly available or easily ascertainable information involving antifungal effectiveness concentrations, animal.
toxicity concentrations, and tissue permeability rates.
For example, non-toxic antifungal agents typically can be directly or indirectly administered in any amount that exhibits antifungal activity within mucus. In addition, antifungal agents that do riot permeate mucosal epithelium typically can be directly administered to the mucus in any amount that exhibits antifungal activity within mucus.
Using the information provided herein, such effective amounts also can be determined by routine experimentation in vitro or in vivo. For example, a patient having a fungus-induced rhinosinusitis can receive direct administration of an antifungal agent in an amount close to the MIC calculated from in vitro analysis. If the patient fails to respond, then the amount can be increased by, for example, ten fold. After receiving this higher .
concentration, the patient can be monitored for both responsiveness to the treatment and toxicity symptoms, and adjustrnents made accordingly.
In one embodiment, the present formulations comprise about O.OI ng to about 1000 mg per kg of body weight of the mammal per administration of formulation, where the formulation is administered directly to the nasal-paranasal mucose.
Antifungal agent particularly suitable for administration are itraconazole, ketoconazole, or voriconazole.
The MIC values for voriconazole range from about 0.003 µg/mL to about 4 :mu.glniL
depending upon the specific fungal organism or isolate tested. For fluconazole, the MIC
values range from about 0.25 µg/mL to greater than about 64 µglmL.
Various factors can influence the actual amount of antifungal agent in the formulations provided herein. For example, the frequency of administration of the formulations, duration of treatrnent, combination of other antifungal agents, site of administration, degree of inflammation, and the anatomical configuration of the treated area may require an increase or decrease in the actual amount of antifungal agent in the present formulations.
Table 1 sets forth preferable ranges and dosages of the antifungal agent of the presentinvention.
Table 1 Antifungal Agents and Dosages Brand PreferableMore Most Most Generic Class PreferablePreferablePreferable Name Name ~nge Ran a Ran a Dose Am hotericinFun Antifun0.5-150 4-30 m 7.5-IS 10 m 'zone al m m 12H
FluconazoleDiflucanAntifun0.5-150 20-70 25-50 10 m al m m m 12H
ltraconazoleS oranoxAntifun0.5-150 20-70 25-50 30 m al m m m 12H
Steroidal Anti-Inflarnmatory Steroidal anti-inflammatories for use herein include fluticasone, beclomethasone, any pharmaceutically acceptable derivative thereof, and any combination thereof. As used herein, a pharmaceutically acceptable derivative includes any salt, ester, enol ether, enol ester, acid, base, solvate or hydrate thereof. Such derivatives may be prepared by those of skill in the art using known methods for such derivatization.
In one alterative embodiment, the steroidal anti-inflammatory agents have a specific particle size distribution profile. As used herein, particle size refers to an average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art, such as, for examples sedimentation field flow fractionation, photon correlation spectroscopy, or disk centrifugation, among other techniques.
Fluticasone Preferably, the intranasal steroid of the present formulations is fluticasone propionate. Fluticasone propionate is a synthetic corticosteroid and has the empirical formula CZSH31F3~SS~ It has the chemical name S-(fluromethyl)6a,9-difluoro-11(3-17-dihydroxy 16a-methyl-3-oxoandrosta-1,4-diene-17~i-carbothioate,17-propionate.
Fluticasone propionate is a white to off white powder with a molecular weight of 500.6 and is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol.
In an embodiment, the formulations of the present invention may comprise a stervidal anti-inflammatory (e.g., fluticasone propionate) having the following particle size distribution profile: about 10% or less of the steroid particles have a particle size of less than 0.90 microns; about 25% or less of the steroid particles have a particle size of less than 1.6 microns; about 50% or less of the steroid particles have a particle size of less than 3.2 microns; about 75% or less of the steroid particles have a particle size of less than 6.10 microns; about 90% or less of the steroid particles have a particle size of less than 10 microns.
In an alternative embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory having the following particle size distribution profile; about 10% of the steroid particles have a particle size of less than 0.70 microns;
about 25% of the steroid particles have a particle size of less than 1.30 microns; about 50% of the steroid particles have a particle size of less than 2.5 microns; about 75% of the steroid particles have a particle size of less than 4.0 microns; about 90% of the steroid particles have a particle size of less than 6.0 microns; and greater than 90% or about 100% of the steroid particles have aparticle size of less than 10 microns. Preferably, the steroid is fluticasone propionate.
In one preferred embodiment, the formulation of the present invention comprises a steroid having the following particle size distribution profile: about 10%
of the steroid particles have a particle size less than 0.50 microns; about 25% of the steroid particles have a particle size less than 0.90 microns; about 50% of the steroid particles have a particle size less than 1.7 microns; about 75% of the steroid particles have a particle size less than 3.5 microns; about 90°l0 of the steroid particles have a particle size less than 5.5 microns.
In another alternative embodiment, greater than 90% or about 100% of the steroid particles have a particle size less than 15 microns, preferably less than 10 microns, more preferably less than 8 microns, most preferably less than 7 microns.
Beclomethasone Also preferably, the steroidal anti-inflammatory of the present formulations is beclomethasone dipropionate or its monohydrate. Beclomethasone dipropionate has the chemical name 9-chloro-llb,I7,21-trihydroxy 16b-methylpregna-1,4-diene-3,20-doine17,21-dipropionate. The compound may be a white~powder with a molecular weight of 521.25; and is very slightly soluble in water (Physicians' Desk Reference.RTl~, very soluble in chloroform, and freely soluble in acetone and in alcohol. ~ ' The formulations of the present invention may comprise a steroidal anti-inflammatory (e.g., beclometasone diproprionate) having the following particle size distribution profile: about 10% or less of the steroid particles have a particle size of less than 0.75 microns; about 25% or less of the steroid particles have a particle size of less than 1.5 microns; about 50% or less of the steroid particles have a particle size of less than 2.0 microns; about 75% or less of the steroid particles have a particle size of less than 3.5 microns; about 90% or less of the steroid particles have a particle size of less than 5.0 microns; and greater than 90% or about 100% of the steroid particles have a particle size of less than 10 microns.
In an alternative embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory having the following particle size distribution profile: about 10% of the steroid particles have a particle size of less than 0.35 microns;
about 25% of the steroid particles have a particle size of less than 0.70 microns; about 50% of the steroid particles have a particle size of less than 1.25 microns; about 75% of the steroid panicles have a particle size of less than 2.0 microns; about 90% of the steroid particles have a particle size of less than 3.0 microns; and greater than 90% or about 100% of the steroid particles have a particle size of less than 6.5 microns. Preferably, the steroid is beclomethasone dipropionate.
In one preferred embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory having the following particle size distribution profile: about 10% of the steroid particles have a particle size less than 0.40 microns;
about 25°/ of the steroid particles have a particle size less than 0.70 microns; about 50% of the steroid particles have a particle size less than 1.3 microns; about 75% of the steroid particles have a particle size less than 2.0 microns; about 90% of the steroid particles have a particle size less than 3.0 microns; greater than 90% or about 100% of the steroid particles have a particle size less than 6.O~microns.
In another alternative embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory having the following particle size distribution profile: about 10% of the steroid particles have a particle size less than 0.60 microns;
25% of the steroid particles have a particle size less than 0.90 microns;
about 50% of the steroid particles have a particle size less than 1.5 microns; about 75% of the steroid particles have a particle size less than 2.5 microns; about 90% of the steroid particles have a particle size less than 3.5 nucrons; greater than 90% or about 100% of the steroid particles have aparticle size~less than 6.0 microns.
In another alternative embodiment, greater than 90% or about 100% of the steroid particles have a particle size less than 15 microns, preferably less than 10 microns, more preferably less than 8 microns, most preferably less than 7 microns. In another preferred embodiment, greater than 90% or about 100% of the steroid particles have a particle size between 4 and 7 microns or 5 and 6 microns. In another embodiment, greater than 90% or about 100% of the steroid particles have a particle size less than 10 microns, preferably less than 7 microns; less than 6 microns; less than 5 microns, or less than 4 microns.
Providing steroidal anti-inflammatories according to the present invention is believed to be a more effective way to provide the medication to the nasal-paranasal region, thereby increasing bioavailability and efficacy of the steroid. It is understood that each of the particle size distribution profiles described in Serial Appl. Nos.
10/41,682 and lOl4I4,756 may be suitable for.any of the anti-inflammatory agents described herein.
The preferred anti-inflammatory agents are fluticasone and beclomethasone.
Also, the dosages described in these applications may also be suitable for use in the present invention. Each of these applications are incorporated herein by reference in their entirety.
Additionally, the formulations of the present invention may comprise fluticasone or beclomethasone alone or in combination with one or more other steroidal anti-inflammatories. Examples of steroidal anti=inflammatories for use herein include,'but are not limited to, betamethasone, triamcinolone, dexamethasone, prednisone, mometasone, flunisolide and budesonide. ' Other anti-inflammatory for use herein are listed below in Table 2.
Table 2 Steroidal Anti-inflammatory Agents and Dosages Most Most Preferable More PreferablePreferablePreferable Generic Brand NameClass Ran Ran a Ran a Dose Name a Ace 1c steineMucomist Mucol 125-S00 150-450 200-400 30D m Mucosil 'cs m m m 12H
Amikacin Amikin Aminoglycoside50-500 75-300 100-200 166 mg mg mg mg Q8-A hotericinFun izone Antifun 2.5-45 4-30 m 7.5-15 10 m 12H
H al m m Atro ine Anticoliner10-700 25-400 75-30 200 me 'c me me me 12H
Azelastine Astelin Antihistamine137-1096 204-822 382-616 411 mcg mcg mcg Q12H
me Azithro Zithromax Macrolide50-400 75-300 150-200 167 m in m m m 12H
Aztreonan Aaactam Monobactam250-1 300-900 475 750 450 m ODO m m 8H
m HeclamethasoneVanceril Steroidal0.1-4 0.2-3 0.2-2 0.8 mg Beclovent Anti- mg mg mg QI2H
inflammato HetamethasoneCelestone Steroidai0.1-4 0.2-3 0.2-2 0.8 mg . Anti- mg mg mg Q12H
inflammato Cefazolin Ancef, Cephlasporin250-1000 300-900 575-700 650 mg FCefzol mg mg mg Q8H
Gen Cefepine Maxipime Cephlasporin12S-1000 200-900 575-700 650 mg mg rng mg QI2H
Gen Cefonicid Moniacid Cephlasporin250-1000 300-900 575-700 600 mg mg mg mg Q24H
Gen CefaperazoneCefobid Cephlasporin250-1000 300-900 575-700 600 mg mg mg mg Q12H
Gen Cefotaxime Claforan Cephlasporin250-1000 300-900 575-700 600 mg mg mg mg Q8-Gen H ' 12H
Cefotetan Cefotan Cephlasporin250-1000 300-900 575-700 600 mg mg mg mg Q8-C ham 12H
cin Cefoxitin Mefoxiri Cephlasporin250-1000 300-900 575-700 600 mg ~ mg mg mg Q12H
-Ceoham cin CeRazidime Fortaz, Cephlasporin250-1000 300-900 475-750 550 mg Ceptaz mg mg mg Q12H
Gen II
CeflizoximeCeflzox Cephlasporin250.1000 300-900 575-?OD 600 mg mg mg mg Q8-Gen 12H
CeftriaxoneRocephin Cephtasporin250-1000 300-900 575-700 650 mg mg mg mg QI2H
Gen II
Cefuroxime Ceftin Cephlasporin100-600 200-520 250-400 285 mg mg mg mg Q8H
Gen II
Cephapirin Cefadyl Cephlasporin250-1000 300-900 575-700 650 mg mg mg mg Q12H
Gen Ci rofloxacinCi o uinolone25-200 50-175 75-110 90 m 12H
m m m Clind cin Cleocin Lincosamide50-600 75-500 125-300 225 m m rn m 12H
Cromolyn lntaIINasalcromMast 5-100 7.5-75 10-50 20 mg Sodium cell mg mg mg Q12H
.
stabilizer DexamethasoneDecadron Steroidal0.1-4 0.2-3 0.2-2 D.8 mg Anti- mg mg mg Q12H
inflammato Domase a1 Pulmo a Mucot 0.5-5 1-4. m 2-3 m 1.5 m ha 'c m 12H
Do c cline Vibra cin Tetrac 10-100 15-80 25-65 Z7 m 12H
cline m m m ErythromycinErythrocinMacrotide50-600 60-350 100-300 150 mg mg mg mg Q8H
Lactobionate FluconazoleDiflucan Antifun 12.5-150 20-70 25-50 30 m 12H
al m m m FlunisolideAerobid Steroidal0.1-4 0.2-3 0.2 2 0.8 mg Nasalide Anti- mg mg mg Q12H
inflammato FlurbiprofenOcofen Nonsteroidal0.01-2 0.05-I 0.1-0.S D.15 mg mg mg mg Q12H
Anti-inflammato FluticasoneFlonase Steroidal10-700 25-400 75-300 200 meg Anti- mcg mcg mcg Q24H
inflammato Gentam cin Garam cin Amino 10-200 30-150 80-120 95 m 8-12H
I oside m m m Ibuprofen Motrin Nonsteroidal25-400 30-300 50150 100 rng mg mg mg Q12H
Anti-inflammato I ratro Atrovent Anticholiner10 25-400 75-300 200 me ium 'c 700 mo me 12H
me ItraconazoleS oranox Antifungal12.5--I5020-70 mg 25-50 30 m 12H
m m Ketorolac Acular Nonsteroidal0.05-4 0.1-2 mg 0.3-I 0.5 mg mg mg QI2H
Anti-inflamatto LevofloxacinLeva uin uinolone40-200 50-150 60-80 70 m 12H
m rn m Linezolid Zyvox Miscellaneous50-600 7S-450 100-300 200 mg mg mg ng QI2H
anti-bacterial Loratidine Clarion Antihistamine0.5-10 1-7.5 m I-5 m 2 m 12H
m Mero enem Merrin Carba 200-75 250-700 300-500 33 m 8H
enem m m m~
MezlacillinMezlin Penicillin 300-1500375-1000 - 833 m m m ?50-950 H
m Miconazole Monistat Antifun 12.5-30030-200 50-100 60 m 12H
al m rii m MontelukastSin ulair Anoleukatriene 0.5-15 2-25 m 3-15 10 m 12H
m m Mu irocin Bactroban Antibacterial 1-25 1.5-20 2-15 10 m 6-8H
m m m Nafcillin Uni en Penicillin 250-1000300-900 575-700 600 m m m m 8H
Nedocromil Tilade Mast 1-25 3-IS mg 5-12 7 mg QI2H
cell rng mg stabilizer Ofloxacin Floxin uinolone 25-200 50-175 75-110 90 m 12H
m m m Oxacillin Prosta Penicillin Z50-1000300-900 575-700 600 m hin m m m 8H
OxymetazolinoAfiin Decongestant 0.05--0.50.075-0.4 0.1-0.3 0.2 mg mg mg QI2H
m Phen 1 herineNeo-S hineDecon 5-50 10-35 m 1S-20 10 m 12H
estant m m Pi eracillinPi racil Penicillin 100-1000125-750 250-600 460 m m m m H
Potassium Antis 30-20 40-150 50-80 60 m 12H
Iodide tic 0 m m m Rifa in ltifadin Miscellaneous _ 1000-4000 1500-35002250 m 500-5000m m 12H
m Taurolin TaurolidineNon 5-200 20-150 40-t20 80 mg antibiotic mg mg mg ' Q12H
antimicrobial Tetrah drozolidineTizine Decon 0.05-D.50.06-0.4 0.1-0.3 0.15 m estant m m m 12H
TicarcillinTimentin Penicillin 500-50001000-4000 1500-35002250 mg + mg mg mg Q6-Clavulanatc gH
Tobra cin Nebcin Aminooside10-200 30-150 80-120 95 m 812H
I m m m TriamcinaloneAsthmacor Steroidal 0.05-3 0.2-2.5 0.5-2 0.6 mg,Ql2H
Anti- mg mg mg Aristacortinflammato Vancomycin Vancocin Antibiotic- 50-400 75-325 125.250 166 mg mg mg mg Q6-8H
miscellaneous X lometazoline~ Otrivin Decon 0.05-0.40.075-03 0.1-0.Z 0125 m estant m m m 12H
ZafirlukastAccolate Antileukotriene 2-60 4-50 m 6-30 20 m 12H
m m Ant1b10tiC
The formulations of the present invention may further comprise an antibiotic.
Additionally, since more than one bacterial organism may be associated with the bacterial infection of the nasal-paranasal region, the present formulations may comprise a broad-spectrum antibiotic such as amoxycillin, erythromycin, or cefadroxil.
Alternatively, a combination of anti-bacterial agents with differing spectra of activity may also be used.
Examples of antibiotics for use in the present invention are shown in Table 3.
Antibiotic Agents and Dosages PreferableMare Most Most Generic Brand . Class gauge PreferablePreferablePreferable Flame Name Itan Ran a Dose a Anukacin Amikin amino 1 1-800 5-500 50-300 I50 m coside m m m SH
~ AzithromycinZithromaxMacrolide 25-400 ~ 75-300L150-200~ 167 ~ ~ ~ mg mg mg mg Q12H
AztreonanAzactam Monobactam150-1000300-900 475-750 450 m CefazolinAncef, Cephlasporinm m m 8H
Kefzol (Gen 150-1000300-900 575-700 650 mg Cefepine I mg mg mg QSH
Maxipime Cephlasporin Cefonicid (Gen 75-1000 200-900 575-?00 650 mg Moniacid IV mg mg mg Q12H
Cefaperazone Cephlasporin Cefobid (Gen 150-1000300-900 575-700 600 mg I mg mg mg Q24H
Cephlasporin (Gen 150-1000300-900 575-700 600 mg ItI mg mg mg Q12H
CefotaximeClaforan Cephlasporin150-1000300-900 575-700 600 mg (Gen mg mg mg Q8-IlI I2H
CefotetanCefotetanCephlasporin150-1000300-900 575-700 600 mg mg mg mg Q8-C ha cin I2H
CefoxitinMefoxia' Cephlasporin150-1000300-900 575-700 600 mg mg mg mg Q12H
C h in Ceftazidime1ortaz, Cephlasporin150-1000300-900 475-750 550 mg Ceptaz (Gen mg mg mg Q12H
CeftizoximeCeBzox Cephiasporin150-1000300-900 575-700 600 mg . (Gen mg mg mg , Q8-CeflriaxoneRocephin Cephlasporin150-1000300-900 575-700 650 mg (Gen mg mg mg Qt2H
n CefuroximeCeftin Cephlasporin50-600 200-520 250-400 285 mg (Gen mg mg mg Q8H
I
CephapirinCefadyl Cephlasporin150-1000300-900 575-700 650 mg (Gen mg mg mg Qt2H
I
Ci rotloxacinCi ro uinolone 15-200 50-175 750110 90 m m m m 12H
Clinda Cleocin Lincosamide25-600 75-500 125-300 225 m cin m m m . 12H
Do line Vibra Tetrac 10-100 15-80 25-65 27 m cin cline m m m 12H
ErythromycinErythtocinMacrolide25-600 60-350 100-300 I50 mg mg mg mg Q8H
Lactobionate GentamicinGaram Amino I-80D 5-500 50-300 150 m cin 1 oside m m m 8H
Kana cin ICantrex Amino 1-800 5-500 50-300 150 m 1 oside m m m 8H
LinezotidZyvox Miscellaneous25-600 75-450 100-300 200 mg mg mg ng Q12H
anti-bacterial MealocillinMezlin Penicillin10D-1500375-1000 750-950 833 m ~ m m m H
M irocin BactrobanAntibacterial1-25 1.520 2-15 10 m m m m d-8H
NafcillinUni en Penicillin150-1000300-900 575-700 600 m m m m 8H
NetilmicinNetro Amino I-800 5-500 50-300 i50 m cin 1 oside m m m 8H
Neom cin M cifradinAmino 1-800 5-500 50-300 I50 m 1 oside m m m SH
OxacillinProsta Penicillin150-1000300-900 575-700 600 m hin m m m 8H
Paromo Humatin Amino I-800 5-500 50-300 150 m cin 1 oside m m m 8H
Pi eracillinPi cil Penicillin50-1000 125-750 250600 460 m m m m H
S to cin Amino 1-800 5-500 50-300 150 m 1 oside m m m 8H
TicarcillinTimentin Penicillin200-50001000-40001500-35002250 + mg mg mg mg Q6-Clawlanaic 8H
Tobra Amino 1-800 5-500 50-300 150 m cin 1 coside m m m 8H
VancomycinVancocin Antibiotic-25-400 75-325 125.250 166 mg mg mg mg Q6-8H
miscellaneous Antiviral Agents The formulations of the present invention may comprise a therapeutically effective amount of one or more antiviral agents. These agents can be administered individually or simultaneously with the steroidal agent of the present invention. The antiviral agent may also include Acyclovir, Famciclovir, Valacyclovir, edoxudine, ganciclovir, foscarnet, cidovir (vistide), Vitl-asert, Formivirsen, HPMPA (9-(3 hydroxy-2-phosphonomethoxypropyl)adenine), PMEA (9-(2-phosphonomethoxyethyl)adenine), IiPMPG (9-(3-Hydroxy-2-(Phosphonomethoxy)propyl)guanine), PMEG (9-[2-(phosphonomethoxy)ethyl]guanine), HPMPC (1-(2-phosphonomethoxy-3-hydroxypropyl)-cytosine), ribavirin, EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamine), pyrazofurin (3-[beta-D-ribofuranosyl]-4-hydroxypyrazole-5-carboxamine), 3-Deazaguanine, GR-92938X (1-beta-D-ribofuranosylpyrazole-3,4-dicarboxamide), LY253963 (1,3,4-thiadiazol-2-yl-cyanamide), RD3-0028 (1,4-dihydro-2,3-Benzodithiin), CL387626 (4,4'-bis[4,6-di[3-aminophenyl-N,N-bis(2-carbamoylethyl)-sulfonilimino]-1,3,5-triazin-2-ylamino-biphenyl-2,2'-disulfonic acid disodium salt), BABIM (Bis[5-Amidino-2-benzimidazolyl]methane), and N1H351.
Other suitable dosages and methods of treatment of the ingredients described herein are described in US 2001/0006944AI, pub. date July 5, 2001, which is incorporated herein by reference in its entirety. .
Other Components The formulation of the present invention may be in any form piovided the formulation can be administered to a mammal in an amount, at a frequency, and for a duration effective to prevent, reduce, or eliminate one or more symptoms associated with Rhinosinusitis, including fungus induced Rhinosinusitis. For example, a formulation within the scope of the invention can be in the form of a solid, liquid, and/or aerosol including, without limitation, powders, crystalline substances, gels pastes, ointments, salves, creams, solutions, suspensions, partial liquids, sprays, nebulae, mists, atomized vapors, tinctures, pills, capsules, tablets, and gelcaps. In addition, the formulation can contain a cocktail of other ingredients, particularly those described herein.
For example, a formulation within the scope of the invention can contain, without limitation, one, two, three, four, five, or more different antifungal agents, antibiotics, antiviral agents, or the other ingredients described herein. Further, formulations within the scope of the invention can contain additional ingredients including, without limitation, pharmaceutically acceptable aqueous vehicles, pharmaceutically acceptable solid vehicles, steroids, mucolytic agents, antibacterial agents,.anti-inflammatory agents, immunosuppressants, dilators, vaso-constrictors, decongestants, leukotriene inhibitors, anti-cholinergics, anti-histamines, therapeutic compounds and combinations thereof.
Such antiviral agents may include IIVIPDH inhibitors, inhibitors of virus adsorption entry, inhibitors of fusion with host cells, antisense oligonucleotides, and nucleoside analogues.
In one embodiment, the present formulations may be provided in any form suitable for intranasal administration. In another alternative embodiment, the formulations of the present invention are in solution or suspension form suitable for intranasal administration.
In an embodiment, the formulation of the present invention may comprise a preservative, suspending agent, wetting agent, tonicity agent andlor diluent.
In one embodiment, the formulations provided herein may comprise from about 0.01 % to about 95%, or about 0.01 % to about 50%, or about 0.01 % to about 25%, or about 0.01 % to about 10%, or about 0.01% to about 5% of one or more pharmacologically suitable suspending fluids which is physiologically acceptable upon administration.
Pharmacologically suitable fluids for use herein include, but are not limited to, polar solvents, including, but not limited to, compounds that contain hydroxyl groups or other polar groups. Solvents include, but are not limited to,. water or alcohols, such as ethanol, isopropanol, and glycols including propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol and polyoxyethylene alcohols. Polar solvents also include protic solvents, including, but not limited to, water, aqueous saline solutions with one or more pharmaceutically acceptable salt(s), alcohols, glycols or a mixture there of. In one alternative embodiment, the water for use in the present formulations should meet or exceed the applicable regulatory requirements for use in drugs.
In certain embodiments herein, the formulations of the present invention have a pH of about 2.0 to about 9Ø Optionally, the formulations of the present invention may contain a pH buffer. For example, a buffer may comprise any known pharmacologically suitable buffexs which are physiologically acceptable upon administration intranasally.
The buffer may be added to maintain the pH of the formulation between about 3.0 and about 7.0, for example.
Sterility or adequate antimicrobial preservation may be provided as part of the present formulations. Since certain formulations of the present invention are intended to be administered intranasally, it is preferred that they be free of pathogenic organisms. 'A
benefit of a sterile liquid suspension is that it reduces the possibility of introducing contaminants into the individual when the suspension formulation is administered intranasally, thereby reducing the chance of an opportunistic infection.
Processes which may be considered for achieving sterility may include any appropriate sterilization steps known in the art.
In one embodiment, the formulation of the present invention is produced under sterile conditions, and the micronization of the steroidal anti-inflammatory is performed in a sterile environment, and the mixing and packaging is conducted under sterile .
conditions. In one alternative embodiment, one or more ingredients in the present formulation may be sterilized by steam, gamma radiation or prepared using or mixing sterile steroidal powder and other sterile ingredients where appropriate.
Also, the formulations may be prepared and handled under sterile conditions, or may be sterilized before or after packaging.
In addition to or in lieu of sterilization, the formulations of the present invention may contain a pharmaceutically acceptable preservative to minimize the possibility of microbial contamination. Additionally, a pharmaceutically-acceptable preservative may be used in the present formulations to increase the stability of the formulations. It should be noted, however, that any preservative must be chosen for safety, as the treated tissues may be sensitive to irntants. Preservatives suitable for use herein include, but are not limited to, those that protect the solution from contamination with pathogenic particles, including phenylethyl alcohol, benzalkonium chloride, benzoic acid, or benzoates such as sodium benzoate. Preferably, the preservative for use in the present formulations is benzalkonium chloride or phenylethyl alcohol: In certain embodiments, the formulations herein comprise from about 0.01% and about 1.0% w/w of benzalkonium chloride, or from about 0.01% and about 1% v/w phenylethyl alcohol. Preserving agents may also be present in an amount from about 0.01% to about 1%, preferably about 0.002% to about 0.02% by total weight or volume of the formulation.
The formulations provided herein may also comprise from about 0.01 % to about 90%, or about 0.01% to about 50%, or about 0.01% to about 25%, or about 0.01%
to about 10%, or about 0.01 % to about 1 % w/w of one or more emulsifying agent, wetting agent or suspending agent. Such agents for use.herein include, but are not limited to, polyoxyethylene sorbitan fatty esters or polysorbates, including, but not limited to, polyethylene sorbitan monooleate (Polysorbate 80), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 65 (polyoxyethylene (20) sorbitan tristearate), polyoxyethylene (20) sorbitan mono-oleate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate; lecithins; algiiiic acid;
sodium alginate; potassium alginate; ammonium alginate; calcium alginate;
propane-1,2-diol alginate; agar; carrageenan; locust bean gum; guar gum; tragacanth;
acacia; xanthan gum; karaya gum; pectin; amidated pectin; ammonium phosphatides;
microcrystalline cellulose; methylcellulose; hydroxypropylcellulose;
hydroxypropylmethylcellulose;
ethylmethylcellulose; carboxymethylcellulose; sodium, potassium and calcium salts of fatty acids; mono-and di-glycerides of fatty acids; acetic acid esters of mono-and di-glycerides of fatty acids; lactic acid esters of mono-and di-glycerides of fatty acids; citric acid esters of mono-and di-glycerides of fatty acids; tartaric acid esters of mono-and di-glycerides of fatty acids; mono-and diacetyltartaric acid esters of mono-and di-glycerides of fatty acids; mixed acetic and tartaric acid esters of mono-and di-glycerides of fatty acids; sucrose esters of fatty acids; sucroglycerides; polyglycerol esters of fatty acids;
polyglycerol esters of polycondensed fatty acids of castor oil; propane-1,2-diol esters of fatty acids; sodium stearoyl-2lactylate; calcium stearoyl-2-lactylate;
stearoyl tartrate;
sorbitan monostearate; sorbitan tristearate; sorbitan monolaurate; sorbitan monooleate;
sorbitan monopalinitate; extract of quillaia; polyglycerol esters of dimerised fatty acids of Soya bean oil; oxidatively polymerised soya bean oil; and pectin extract. Tn certain embodiments herein, the present formulations comprise polysorbate 80, microcrystalline cellulose, carboxymethylcellulose sodium and/or dextrose.
The present formulations may further comprise from about 0.01% to about 90%, or about 0.01% to about 50%, or about 0.01% to about 25%, or about 0.01% to about 10%, or about 0.01% to about 1% wlw of one or more excipients and additives which are pharmacologically suitable. Excipients and additives generally have no pharmacological activity, or at least no undesirable pharmacological activity. The concentration of these may vary with the selected agent, although the presence or absence of these agents, or their concentration is not an essential feature of the invention. The excipients and additives may include, but are not limited to, surfactants, moisturizers, stabilizers, complexing agents, antioxidants, or other additives known in the art.
Complexing agents include, but are not limited to, ethylenediaminetetraacetic acid (EDTA) or a salt thereof, such as the disodium salt, citric acid, nitrilotriacetic acid and the'salts thereof. In another embodiment, particularly in the suspension formulations provided herein, the cornplexing agent is sodium edetate. In one embodiment, the compositions contain sodium edetate at a concentration of about 0.05 mg/mL to about 0.5 mg/mL, or about 0.1 mg/mL to about 0.2 mg/mL. Also, for example, the formulations of the present invention may comprise from about 0.001% to about 5% by weight of a humectant to inhibit drying of the mucous membrane and to prevent irntation. Any of a variety of pharmaceutically acceptable humectants can be employed, including sorbitol, propylene glycol, polyethylene glycol, glycerol or mixtures thereof, far example.
The formulations provided herein also may comprise about 0.01% to about 90%, or about 0.01% to about 50%, or about 0.01% to about 25%, or about 0.01% to about 10%, or about 0.01 % to about 10% w/w of one or more solvents or co-solvents to increase the solubility of any of the components of the present formulations.
Solvents or co-solvents for use herein include, but are not limited to, hydroxylated solvents or other pharmaceutically- acceptable polar solvents, such as alcohols including isopropyl alcohol, glycols such as propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, and polyoxyethylene alcohols. In another embodiment, the formulations of the present invention may comprise one or more conventional diluents known in the art. The preferred diluent is purified water.
Tonicity agents may include, but are not limited to, sodium chloride, potassium chloride, zinc chloride, calcium chloride and mixtures thereof. Other osmotic.adjusting agents may also include, but are not limited to, mannitol, glycerol, and dextrose or mixtures thereof. In an alternative embodiment, the present formulation may comprise about 0.01% to about 10% w/w, or about 1% to about 8% w/w, or 1% to about 6%
w/w, preferably about 5.0% wlw. The preferred tonicity agent is anhydrous dextrose.
In one alternative embodiment, the formulations of the present invention are stable. As used herein, the stability of formulations provided herein refers to the length of time at a given temperature that greater than 80%, 85%, 90% or 95% of the initial amount of the active ingredients is present in the formulation. For example, the formulations provided herein may be stored between about 15°C and about 30°C, and remain stable for at least 1, 2, 12,18, 24 or 36 months. Also, the formulations may be suitable for administration to a subject in need thereof after storage for more than 1, 2, 12,18, 24 or 36 months at 25°. Also, in another alternative embodiment, using Arrhenius Kinetics, more than 80%, or more than 85%, or more than 90%, or more than 95%
of the initial amount of active ingredients remains after storage of the formulations for more than 1, 2,12, 18, 24 or 36 months between about 15°C and about 30°C.
The formulations of the present invention may be manufactured in any conventional manner known in the art, or by minor modification of such means.
For example, the formulations may be manufactured by thoroughly mixing the ingredients described herein at ambient or elevated temperatures in order to achieve solubility of ingredients where,appropriate.
The preparation of the steroidal inflammatory of the present invention, e.g., fluticasone propionate and beclomethasone dipropionate, having a specific particle size distribution profile may be obtained by any conventional means lmown in the art, or by minor modification of such means. For example, suspensions of drug particles can rapidly undergo particulate size reduction when subj ected to "j et milling"
(high pressure particle in liquid milling) techniques. Other known methods for reducing particle size into the micrometer range include mechanical milling, the application of ultrasonic energy and other techniques.
In addition, the formulations of the present invention may comprise any of the following components: (r) antihistamine: (ii) non-steroidal anti-flarnmatories; (iii) decongestants; (iv) mucolytics; (v) anticholinergics; or (vi) mass cell stabilizers.
Examples of such components are found in U.S. 2002/0061281 Al, published May 23, 2002., This reference is incorporated herein by reference in its entirety.
In one alternative embodiment, the present~invention is directed to a pharmaceutical composition that may be useful in treating rhinosinusitis caused by Alpha Hemolytic Sreptococci, Beta Hemolytic Streptococci, Branhamella Catarrhalis, Diptheroids, Heaemophilis influenza (beta-lactamase positive and negative), Moraxella species, Psuedomonas aeroguinosa, Pseudomas maltophilia, Serratia marcesns, Staphylococcus aureus, Streptococcus pheumonia, Aspergillosis, Mucor and Candida albicans, Flusarium, Curvularia, crytococcus, coccidiodes, and histoplasma.
Mode of Administration Administration of the present formulations can be any type of administration that places the present formulations in contact with nasal-paranasal mucosa. Direct intranasal administration includes, without. limitation, nasal irrigations, nasal sprays, nasal inhalations, and nasal packs with, for example, saturated gauze provided the administered agent contacts nasal-paranasal mucosa prior to crossing epithelium. In addition, injections into the nasal-paranasal cavities using, for example, a needle or catheter tube is considered a direct intranasal administration provided the administered agent contacts nasal-paranasal mucosa after leaving the needle or catheter tube and prior to crossing epithelium. Any device can be used to directly administer the present formulations intranasally including, without limitation, a syringe, bulb,, inhaler, canister, spray can, nebulizer, and mask.
Indirect administration to the nasal-paranasal anatomies can include, without limitation, oral, intravenous, intradermal, and intraperitoneal administrations provided the administered agent contacts nasal-paranasal mucosa. In addition, any device can be used to indirectly administer an agent to the nasal-paranasal anatomy including, without limitation, a syringe and regulated release capsule.
The present formulations may be packaged in any conventional manner suitable for administration of the present formulations. Spray administration containers for various types of nasal formulations have been known in the past and substantially all will be equally suitable for the present formulations, provided that the container materials is compatible with the formulation. In an embodiment, the formulation of the present invention herein is packaged in a container such that it can be dispersed as a mist to be directed into each nostril. For. example, the container may be made of flexible plastic such that squeezing the bottle's sides impels the spray out through the nozzle into the nasal cavity. Alternatively, a small pump button may pump air into the container and cause the liquid spray to be emitted on the return stroke when pressed.
In an alternative embodiment, the formulations of the present invention are packaged in a container pressurized with a gas which is inert to the user and to the ingredients of the solution. The gas may be dissolved under pressure in the container or may be generated by dissolution or reaction of a solid material which forms the gas as a product of dissolution or as a reaction product. Suitable inert gases which can be used herein include nitrogen, argon, and carbon dioxide. Also, the formulations herein may be administered as a spray or aerosol wherein the formulation is packaged in a pressurized container with a liquid propellant such as dicholorodifluoro methane or chlorotrifluoro ethylene, or other propellant. .
Preferably, the present formulations are packaged in a metered dose spray pump, or metering atomizing pump, such that each actuation of the pump delivers a fixed volume of the formulation (i.e. per spray-unit). For administration in drop or other topical form, the formulations herein may suitably be packaged in~a container provided with a conventional dropperlclosure device, comprising a pipette or the like, preferably delivering a substantially fixed volume of the formulation.
Method of Treatment The present invention is also directed to a method for treating rhinosinusitis, including fungus-induced rhinosinusitis. In one embodiment, the method of treating rhinosinusitis of the present invention comprises the step of administering a therapeutically effective amount of the formulation of the present invention to a mammal in need thereof. The formulation may comprise the steroidal agent of the present invention alone or in combination with an anti-fungal agent, an antibiotic or antiviral agent. The formulation is preferably administered intranasally. In one embodiment, the formulation is administered directly to the nasal-paranasal mucosa. In an alternative embodiment, the formulation is administered intranasally via a metered dose spray.pump.
In general, the course of treatment for any individual with respect to any of the active ingredients described herein can be readily determined by his or her physician.
The method of the present invention may further comprise administering the formulation of the present for a duration or frequency sufficient to treat one or more symptoms of rhinosinusitis, including fungus-induced rhinosinusitis. For example, the formulation may be administered one time to about 10 times a day for about one day.to about 100 days or more, or until such fungus-induced rhinosinusitis is treated. In an embodiment, the method of the present invention comprises administering to a mammal diagnosed with fungus-induced rhinosinusitis a formulation comprising a therapeutically effective amount of an antifungal agent and a steroidal anti-inflammatory intranasally via a metered dose spray pump one to three times a day for up to two weeks. In an alternative embodiment, the administration of the present formulations may comprise 1, 2, 3, 4, 5, 6, 7 or 8 applications of the present fornnulativn to the nasal-paranasal mucosa one, two, three, four or five times a day.
In an alternative embodiment, the formulation of the method of the present invention further comprises an antibiotic. However, when administering antibiotics, physicians must keep in mind the incidence of drug-resistant bacteria in their community and consider the patient's overall health status. Special attention should be given to diseases that could impede normal recovery from infection and/or predispose to complications (e.g., diabetes mellitus, chronic pulmonary disease, asthma, cystic fibrosis and immune deficiencies). Additionally, physicians should consider whether or not the patient is immunocomprimised in selecting an antibiotic. In one embodiment, the antibiotic is administered for a period of 1 day to about 10 weeks. Iwan alternative embodiment, the antibiotic is administered for about .1 day to about 28 days.
Accordingly, the present invention provides a method of treating fungus-induced rhinosiriusitis associated with a bacterial infection in the nasal paranasal region, comprising the steps of administering a formulation comprising an antifungal agent, steroidal anti-inflammatory, and antibiotic until said bacterial infection is cured, and then administering a formulation comprising an antifungal agent and steroidal anti-.
inflammatory.
In an alternative embodiment, the present invention provides a method of treating fungus-induced rhinosinusitis, comprising the steps of administering a formulation comprising a steroidal anti-inflammatory alone or in combination or in conjunction with an antifungal agent, antibiotic or antiviral agent. For example, the steroidal agent may be administered separately from the antif-.ungal agent ox antibiotic, or each ingredient can be administered simultaneously (e.g., in a single formulation) concurrently, subsequently, or in tandem. In another embodiment, each ingredient is administered individually in its own formulation and pursuant to an appropriate dosage regimen for that particular ingredient. Suitable dosage regimens for steroidal agents, fungal agents, antibiotics or antiviral agents are known by those skilled in the art.
V. EXAMPLES
Examples 1-5 herein are prophetic examples provided to illustrate, but riot to limit, the formulations and methods of the present invention. They are presented with the understanding that changes can be and may need to be made to a specific composition in order to obtain or optimize the formulation. Such modifications to the following prophetic examples, if needed, are normal and understandable to those of ordinary skill in the art, and shall not be used to limit the invention.
It is believed that prophetic examples 1-5 would be suitable for administration to the nasal-paranasal mucosa of an individual suffering from fungus-induced rhinosinusitis associated with a bacterial infection. The formulations may be sterile. It is understood that the steroid, antibiotic, antifungal agent or the other ingredients described herein may be administered in the same formulation, or may be administered individually, or in any combination thereof.
Example 1 Am hotericin B 2.0 -100.0 m ml Neom cin Sulfate 5.0 -100.0 m ml Phen leth 1 Alcohol 0.5 -10.0 m .ml Fluticasone Pro innate 0.25 -1.0 m mI
Microc stalline Cellulose S.0 -15.0 m ml ' Pol orbate 80 0.1-1.0 mg/ml Purified Water - q.s.
Example 1 is a prophetic example of a formulation of the present invention, wherein about 10% of the fluticasone propionate particles have a particle size of less than 0.70 microns; about 25% of the fluticasone propionate particles have a particle size of less than 1.30 microns; about 50% of the fluticasone propionate particles have a particle size of less than 2.5 microns; about 75% of the fluticasone propionate particles have a particle size of less than 4.0 microns; about 90% of the fluticasone propionate particles have a particle size of less than 6.0 microns; and greater than 90% or about 100% of the fluticasone propionate particles have a particle size of less than 10 microns. The solution of Example 1 may be made by methods known to those of ordinary skill in the art.
Example 2 Fluconazole _ _ 1.0 - 20.0 m ml Neomycin Sulfate 5.0 -100.0 m ml Phen leth 1 Alcohol 0.5 -10.0 m ml Fluticasone Pro innate 0.25 -1.0 m ml Microcrystalline Cellulose5.0 -15.0 mg/ml Pol sorbate 80 0.1-1.0 m ml Purified Water .s.
Example 2 is a prophetic example of a formulation of the present invention, wherein about 10% of the fluticasone propionate particles have a particle size of less than 0.70 microns; about 25% of the fluticasone propionate particles have a particle size of less than 1.30 microns; about 50% of the fluticasone propionate particles have a particle size of less than 2.5 microns; about 75% of the fluticasone propionate particles have a .
particle size of less than 4.0 microns; about 90% of the fluticasone propionate particles have a particle size of less than 6.0 microns; and greater than 90% or about 100% of the fluticasone propionate particles have a particle size of less than 10 microns.
The solution of Example 2 may be made by methods known to those of ordinary skill in the art.
Example 3 Am hotericin B 2.0 -100.0 m ml Neom cin Sulfate 5.0 -100.0 m ml Benzalkonium Chloride 0.1- 0.5 rn ml Dextrose 20.0 -100.0 Phen ' leth 1 Alcohol 0.5 -10.0 m .ml Beclomethasone Di ro 0.25 -1.0 m ml innate Purified Water .s.
Example 3 is a prophetic example of a formulation of the present invention, wherein about 10% of the beclomethasone dipropionate particles have a particle size less than 0.40 nucrons; about 25% of the beclomethasone dipropionate particles have a .
particle size less than 0.'70 microns; about 50% of the beclomethasone dipropionate particles have a particle size less than 1.3 microns; about 75% of the beclomethasone dipropionate particles have a particle size less than 2.0 microns; about 90%
of the beclomethasone dipropionate particles have a particle size less than 3.0 microns; and greater than 90% or about 100% of the beclomethasone dipropionate particles have a particle size less than 6.0 microns. Example 3 may be made by methods known to those of ordinary skill in the art.
Example 4 Fluconazole 1.0 - 20.0 m ml Neom cin Sulfate 5.0 -100.0 m ml Benzalkonium Chlaride 0.1- 0.5 m ml ' Dextrose '20.0 -100.0 Phen leth 1 Alcohol 0.5 -10.0 m .ml Beclomethasone Di ro 0.25 -1.0 m ml innate Purified Water .s.
Example 4 is a prophetic example of a formulation of the present invention, wherein about 10% of the beclomethasone dipropionate particles have a particle size less than 0.40 microns; about 25% of the beclomethasone dipropionate particles have a particle size less than 0.70 microns; about 50% of the beclomethasone dipropionate particles have a particle size less than 1.3 microns; about 75% of the beclomethasone dipropionate particles have a particle size Iess than 2.0 microns; about 90%
of the beclomethasone dipropionate particles have a particle size less than 3.0 microns; and greater than 90% or about I00% of the beclomethasone dipropionate particles have a particle size less than 6.0 microns. Example 4 may be made by methods known to those of ordinary skill in the art.
Example 5 Fluconazole . 1.0 - 20.0 m /m1 Benzalkonium Chloride 0.1- 0.5 m ml Dextrose 20.0 -100.0 Phen leth 1 Alcohol 0.5 -10.0 m .ml Beclomethasone Di ro 0.25 -1.0 mg/m1 innate Purified Water .s.
Example 5 is a prophetic example of a formulation of the present invention, wherein about 10% of the beclomethasone dipropionate particles have a particle size less than 0.40 microns; about 25% of the beciomethasone dipropionate particles have a particle size less than 0.70 microns; about 50% of the beclomethasone dipropionate particles have a particle size less than 1.3 microns; about 75% of the becloriiethasone dipropionate particles have a particle size less than 2.0 microns; about 90%
of the beclomethasone dipropionate particles have a particle size less than 3.0 microns; and greater than 90% or about 100% of the beclomethasone dipropionate particles have a particle size less than 6.0 microns. Example 5 may be made by methods known to those of ordinary skill in the art.
The Examples herein are presented for illustrative purposes only. They are not intended to limit the scope of the invention. Further, it should be understood that various changes and modifications to the embodiment described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims. Also, the invention may suitably comprise, consist of or consist essentially of the elements or steps described herein. Further, the invention described herein suitably may comprise or be practiced in the absence of any element or step which is not specifically disclosed herein. Further, one or more step described herein may be performed simultaneously with another step.
Claims (70)
1. ~A formulation for the treatment of fungus-induced rhinosinusitis in a mammal, said formulation comprising:
(a) ~about 1 to about 700 mcg of a steroidal anti-inflammatory, wherein the steroidal anti-inflammatory is fluticasone or a pharmaceutically acceptable derivative thereof, said steroidal anti-inflammatory having the following particle size distribution profile:
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.90 microns;
ii. ~about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.6 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a particle size of less than 3.2 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size of less than 6.2 microns; and v. ~about 90% of the steroidal anti-inflammatory particles have a particle size of less than 10.0 microns;
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
(a) ~about 1 to about 700 mcg of a steroidal anti-inflammatory, wherein the steroidal anti-inflammatory is fluticasone or a pharmaceutically acceptable derivative thereof, said steroidal anti-inflammatory having the following particle size distribution profile:
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.90 microns;
ii. ~about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.6 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a particle size of less than 3.2 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size of less than 6.2 microns; and v. ~about 90% of the steroidal anti-inflammatory particles have a particle size of less than 10.0 microns;
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
2. ~A formulation for the treatment of fungus-induced rhinosinusitis in a mammal, said formulation comprising:
i) ~about 1 to about 700 mcg a steroidal anti-inflammatory, wherein the steroidal anti-inflammatory is beclomethasone or a pharmaceutically acceptable derivative thereof, sand steroidal anti-inflammatory having the following particle size distribution profile:
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.75 microns;
ii. ~about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.5 microns;
iii, ~about 50% of the steroidal anti-inflammatory particles have a particle size of less than 2.0 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size of less than 3.5 microns; and v. ~about 90% of the steroidal anti-inflammatory particles have a particle size of less than 5.0 microns.
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
i) ~about 1 to about 700 mcg a steroidal anti-inflammatory, wherein the steroidal anti-inflammatory is beclomethasone or a pharmaceutically acceptable derivative thereof, sand steroidal anti-inflammatory having the following particle size distribution profile:
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.75 microns;
ii. ~about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.5 microns;
iii, ~about 50% of the steroidal anti-inflammatory particles have a particle size of less than 2.0 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size of less than 3.5 microns; and v. ~about 90% of the steroidal anti-inflammatory particles have a particle size of less than 5.0 microns.
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
3. The formulation of claims 1 or 2, further comprising about 0.5 to about 150 mg of an antifungal agent.
4. The formulation of claim 3, wherein the antifungal agent is amphotericin .beta..
5. The formulation of claim 3, wherein said formulation comprises about 7.5 to about 15 mg of amphotericin .beta..
.beta.
.beta.
6. The formulation of claim 3, wherein said formulation comprises about 10 mg of amphotericin ~3.
7. The formulation of claim 3, wherein said formulation comprises about 20 to about 70 mg of fluconazole or itraconazole.
The formulation of claim 3, wherein said formulation comprises about 25 to about 50 mg of fluconazole or itraconazole.
9. The formulation of claim 3, wherein said formulation comprises about 30 mg of fluconazole or itraconazole.
10. The formulation of claim 1, comprising about 25 to about 400 mcg of said steroidal anti-inflammatory.
11. The formulation of claim 1, comprising about 75 to about 300 mcg of said steroidal anti-inflanunatory.
12. The formulation of claim 1, comprising about 200 mcg of said steroidal anti-inflammatory.
13. The formulation of claim 10, wherein the steroidal anti-inflammatory has the following particle size distribution profile:
i. about 10% or less of the steroidal anti-inflammatory particles have a particle size of less than 0.90 microns;
ii. about 25% or less of the steroidal anti-inflammatory particles have a particle size of less than 1.6 microns;
iii. about 50% or less of the steroidal anti-inflammatory particles have a particle size of less than 3.2 microns;' iv. ~about 75% or less of the steroidal anti-inflammatory particles have a particle size of less than 6.10 microns; and, v. ~about 90% or less of the steroidal anti-inflammatory particles have a particle size of less than 10 microns.
i. about 10% or less of the steroidal anti-inflammatory particles have a particle size of less than 0.90 microns;
ii. about 25% or less of the steroidal anti-inflammatory particles have a particle size of less than 1.6 microns;
iii. about 50% or less of the steroidal anti-inflammatory particles have a particle size of less than 3.2 microns;' iv. ~about 75% or less of the steroidal anti-inflammatory particles have a particle size of less than 6.10 microns; and, v. ~about 90% or less of the steroidal anti-inflammatory particles have a particle size of less than 10 microns.
14. ~The formulation of claim 1, wherein the steroidal anti-inflammatory is fluticasone propionate having the following particle size distribution profile:
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.70 microns;
ii. ~about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.30 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a particle size of less than 2.5 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size of less than 4.0 microns;
v. ~about 90% of the steroid particles have a particle size of less than 6.0 microns; and, vi. ~greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size of less than 10 microns.
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.70 microns;
ii. ~about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.30 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a particle size of less than 2.5 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size of less than 4.0 microns;
v. ~about 90% of the steroid particles have a particle size of less than 6.0 microns; and, vi. ~greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size of less than 10 microns.
15. ~The formulation of claim 1, wherein the steroidal anti-inflammatory is fluticasone propionate having the following particle size distribution profile:
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.50 microns;
ii, ~about 25% of the steroidal anti-inflammatory particles have a particle size less than 0.90 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a~
particle size less than 1.7 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size less than 3.5 microns; and, v, ~about 90% of the steroidal anti-inflammatory particles have a particle size less than 5.5 microns.
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.50 microns;
ii, ~about 25% of the steroidal anti-inflammatory particles have a particle size less than 0.90 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a~
particle size less than 1.7 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size less than 3.5 microns; and, v, ~about 90% of the steroidal anti-inflammatory particles have a particle size less than 5.5 microns.
16. ~The formulation of claim 2, comprising about 0.2 to about 3 mg of said steroidal anti-inflammatory.
17. ~The formulation of claim 2, comprising about 0.2 to about 2 mg of said steroidal anti-inflammatory.
18. ~The formulation of claim 2, comprising about 0.8 mg of said steroidal anti-inflammatory.
19. ~The formulation of claim 16, wherein the steroidal anti-inflammatory has the following particle size distribution profile:
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.35 microns;
ii. ~about 25% of the steroidal anti-inflammatory particles have a particle size of less than 0.70 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a particle size of less than 1.25 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size of less than 2.0 microns;
v. ~about 90% of the steroidal anti-inflammatory particles have a particle size of less than 3.0 microns; and, vi. ~greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size of less than 6.5 microns.
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.35 microns;
ii. ~about 25% of the steroidal anti-inflammatory particles have a particle size of less than 0.70 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a particle size of less than 1.25 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size of less than 2.0 microns;
v. ~about 90% of the steroidal anti-inflammatory particles have a particle size of less than 3.0 microns; and, vi. ~greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size of less than 6.5 microns.
20. ~The formulation of claim 16, wherein the steroidal anti-inflammatory has the following particle size distribution profile:
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.40 microns;
ii. ~about 25% of the steroidal anti-inflammatory particles have a particle size less than 0.70 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a particle size less than 1.3 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size less than 2.0 microns;
v, ~about 90% of the steroidal anti-inflammatory particles have a particle size less than 3.0 microns; and, vi. ~greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size less than 6.0 microns.
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.40 microns;
ii. ~about 25% of the steroidal anti-inflammatory particles have a particle size less than 0.70 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a particle size less than 1.3 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size less than 2.0 microns;
v, ~about 90% of the steroidal anti-inflammatory particles have a particle size less than 3.0 microns; and, vi. ~greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size less than 6.0 microns.
21. ~The formulation of claim 16, wherein the steroidal anti-inflammatory is beclomethasone dipropionate having the following particle size distribution profile:
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.60 microns;
ii. ~25% of the steroidal anti-inflammatory particles have a particle size less than 0.90 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a particle size less than 1.5 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size less than 2.5 microns;
v. ~about 90% of the steroidal anti-inflammatory particles have a particle size less than 3.5 microns; and, vi. ~greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size less than 6.0 microns.
i. ~about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.60 microns;
ii. ~25% of the steroidal anti-inflammatory particles have a particle size less than 0.90 microns;
iii. ~about 50% of the steroidal anti-inflammatory particles have a particle size less than 1.5 microns;
iv. ~about 75% of the steroidal anti-inflammatory particles have a particle size less than 2.5 microns;
v. ~about 90% of the steroidal anti-inflammatory particles have a particle size less than 3.5 microns; and, vi. ~greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size less than 6.0 microns.
22. ~The formulation of claim 1, wherein the formulation is sterile.
23. ~The formulation of claim 1, wherein the formulation further comprises a preservative.
24. ~The formulation of claim 23, wherein the preservative is benzalkonium chloride.
25. ~The formulation of claim 1, wherein the formulation is stable.
26. ~The formulation of claim 1, wherein the formulation is an aqueous suspension or aqueous solution.
27. ~The formulation of claim 26, wherein.the formulation is in a metered-dose spray pump bottle.
28. ~The formulation of claim 26, further comprising about 0.01% to about 90% by weight on a dried weight basis of one or more of the following compounds:
(a) microcrystalline cellulose;
(b) carboxymethyl cellulose sodium;
(c) dextrose;
(d) benzalkonium chloride;
(e) polysorbate 80; and (g) phenylethyl alcohol.
(a) microcrystalline cellulose;
(b) carboxymethyl cellulose sodium;
(c) dextrose;
(d) benzalkonium chloride;
(e) polysorbate 80; and (g) phenylethyl alcohol.
29. ~The formulation of claim 1, further comprising an antibiotic.
30. ~The formulation of claim 29, wherein the antibiotic is one or more selected from the group consisting of Amikacin, Azithromycin, Aztreonan, Cefazolin, Cefepine, Cefonicid, Cefaperazone, Cefotaxime, Cefotetan, Cefoxitin, Ceftazidime, Ceftizoxime, Ceftriaxone, Cefuroxime, Cephapirin, Ciprofloxacin, Clindamycin, Doxycycline, Erythromycin Lactobionate, Gentamicin, Kanamycin, Linezolid, Mezlocillin, Mupirocin, Nafcillin, Netihnicin, Neomycin, Oxacillin, Paromomycin, Piperacillin, Streptomycin, Ticarcillin, Tobramycin, and Vancomycin.
31. ~The formulation of claim 29, wherein the formulation comprises about 1 to about 800 mg of neomycin sulfate.
32. ~The formulation of claim 29, wherein the formulation comprises about 5 to about 500 mg of neomycin sulfate.
33. ~The formulation of claim 29, wherein the formulation comprises about 50 to about 300 mg of neomycin sulfate.
34. ~The formulation of claim 29, wherein the formulation comprises about 150 mg of neomycin sulfate.
35. ~A formulation for the treatment of fungus-induced rhinosinusitis, said formulation comprising:
(a) ~about 7.5 to about 15 mg of amphotericin .beta.;
(b) ~about 75 to about 300 mcg of the steroidal anti-inflammatory fluticasone propionate having the following particle size distribution profile:
ii. ~about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.70 microns;
iii, ~about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.30 microns;
iv. ~about 50% of the steroidal anti-inflammatory particles have a particle size of less than 2.5 microns;
v. ~about 75% of the steroidal anti-inflammatory particles have a particle size of less than 4.0 microns;
vi. ~about 90% of the steroid particles have a particle size of less than 6.0 microns; and, vii, ~greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size of less than 10 microns.
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
(a) ~about 7.5 to about 15 mg of amphotericin .beta.;
(b) ~about 75 to about 300 mcg of the steroidal anti-inflammatory fluticasone propionate having the following particle size distribution profile:
ii. ~about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.70 microns;
iii, ~about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.30 microns;
iv. ~about 50% of the steroidal anti-inflammatory particles have a particle size of less than 2.5 microns;
v. ~about 75% of the steroidal anti-inflammatory particles have a particle size of less than 4.0 microns;
vi. ~about 90% of the steroid particles have a particle size of less than 6.0 microns; and, vii, ~greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size of less than 10 microns.
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
36. ~A formulation for the treatment of fungus-induced rhinosinusitis, said formulation comprising:
(a) ~about 7.5 to about 15 mg of amphotericin .beta.;
(b) about 0.2 to about 2 mg of the steroidal anti-inflammatory beclomethasone dipropionate having the following particle size distribution range;
ii. about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.40 microns iii. about 25% of the steroidal anti-inflammatory particles have a particle size less than 0.70 microns;
iv. about 50% of the steroidal anti-inflammatory particles have a particle size less than 1.3 microns;
v. about 75% of the steroidal anti-inflammatory particles have a particle size less than 2.0 microns;
vi. about 90% of the steroidal anti-inflammatory particles have a particle size less than 3.0 microns; and, vii. greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size less than 6.0 microns;
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
(a) ~about 7.5 to about 15 mg of amphotericin .beta.;
(b) about 0.2 to about 2 mg of the steroidal anti-inflammatory beclomethasone dipropionate having the following particle size distribution range;
ii. about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.40 microns iii. about 25% of the steroidal anti-inflammatory particles have a particle size less than 0.70 microns;
iv. about 50% of the steroidal anti-inflammatory particles have a particle size less than 1.3 microns;
v. about 75% of the steroidal anti-inflammatory particles have a particle size less than 2.0 microns;
vi. about 90% of the steroidal anti-inflammatory particles have a particle size less than 3.0 microns; and, vii. greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size less than 6.0 microns;
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
37. The formulation of claim 35 or 36, further comprising about 50 to about 250 mg of the antibiotic neomycin sulfate.
38. The formulation of claim 37, wherein said formulation is a sterile aqueous solution or aqueous suspension suitable for administration to the nasal-paranasal mucosa via a metered-dose spray pump bottle.
39. The formulation of claim 38, further comprising about 0.01% to about 90% by weight on a dried weight basis of one or more of the following compounds:
(a) microcrystalline cellulose;
(b) carboxymethyl cellulose sodium;
(c) dextrose;
(d) benzalkonium chloride;
(e) polysarbate 80; and (g) phenylethyl alcohol.
(a) microcrystalline cellulose;
(b) carboxymethyl cellulose sodium;
(c) dextrose;
(d) benzalkonium chloride;
(e) polysarbate 80; and (g) phenylethyl alcohol.
40. A formulation for the treatment of fungus-induced rhinosiriusitis, said formulation comprising:
(a) about 25 to about 45 mg of fluconazole or itraconazole;
(b) about 75 to about 300 mcg of the steroidal anti-inflammatory fluticasone propionate having the following particle size distribution profile:
ii. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.70 microns;
iii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.30 microns;
iv. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 2.5 microns;
v. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 4.0 microns;
vi. about 90% of the steroid particles have a particle size of less than 6.0 microns; and, vii. greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size of less than 10 microns.
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
(a) about 25 to about 45 mg of fluconazole or itraconazole;
(b) about 75 to about 300 mcg of the steroidal anti-inflammatory fluticasone propionate having the following particle size distribution profile:
ii. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.70 microns;
iii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.30 microns;
iv. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 2.5 microns;
v. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 4.0 microns;
vi. about 90% of the steroid particles have a particle size of less than 6.0 microns; and, vii. greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size of less than 10 microns.
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
41. A formulation for the treatment of fungus-induced rhinosinusitis, said formulation comprising:
(a) about 25 to about 45 mg of fluconazole or itraconazole;
(b) about 0.2 to about 2 mg of the steroidal anti-inflammatory beclomethasone dipropionate having the following particle size distribution range;
ii. about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.40 microns iii. about 25% of the steroidal anti-inflammatory particles have a particle size less than 0.70 microns;
iv. about 50% of the steroidal anti-inflammatory particles have a particle size less than L3 microns;
v. about 75% of the steroidal anti-inflammatory particles have a particle size less than 2.0 microns;
vi. about 90% of the steroidal anti-inflammatory particles have a particle size less than 3.0 microns; and, vii. greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size less than 6.0 microns;
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
(a) about 25 to about 45 mg of fluconazole or itraconazole;
(b) about 0.2 to about 2 mg of the steroidal anti-inflammatory beclomethasone dipropionate having the following particle size distribution range;
ii. about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.40 microns iii. about 25% of the steroidal anti-inflammatory particles have a particle size less than 0.70 microns;
iv. about 50% of the steroidal anti-inflammatory particles have a particle size less than L3 microns;
v. about 75% of the steroidal anti-inflammatory particles have a particle size less than 2.0 microns;
vi. about 90% of the steroidal anti-inflammatory particles have a particle size less than 3.0 microns; and, vii. greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size less than 6.0 microns;
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
42. The formulation of claim 40 or 41, further comprising about 50 to about 250 mg of the antibiotic neomycin sulfate.
43. The formulation of claim 42, wherein said formulation is a sterile aqueous solution or aqueous suspension suitable for administration to the nasal-paranasal mucosa via a metered-dose spray pump bottle.
44. The formulation of claim 43, further comprising about 0.01 % to about 90% by weight on a dried weight basis of one or more of the following compounds:
(a) microcrystalline cellulose;
(b) carboxymethyl cellulose sodium;
(c) dextrose;
(d) benzalkonium chloride;
(e) polysarbate 80; and (g) phenylethyl alcohol.
(a) microcrystalline cellulose;
(b) carboxymethyl cellulose sodium;
(c) dextrose;
(d) benzalkonium chloride;
(e) polysarbate 80; and (g) phenylethyl alcohol.
45. A method of treating fungus-induced rhinosinusitis in a mammal, said method comprising the steps of applying to the mammal's nasal-paranasal mucosa a formulation comprising:
(a) about 1 to about 700 mcg of a steroidal anti-inflammatory, wherein the steroidal anti-inflammatory is fluticasone or a pharmaceutically acceptable derivative thereof, said steroidal anti-inflammatory having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.90 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.6 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 3.2 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 6.2 microns; and v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 10.0 microns.
(a) about 1 to about 700 mcg of a steroidal anti-inflammatory, wherein the steroidal anti-inflammatory is fluticasone or a pharmaceutically acceptable derivative thereof, said steroidal anti-inflammatory having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.90 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.6 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 3.2 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 6.2 microns; and v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 10.0 microns.
46. A method of treating fungus-induced rhinosinusitis in a mammal, said method comprising the steps of applying to the mammal's nasal-paranasal mucosa a formulation comprising:
(a) about 1 to about 700 mcg a steroidal anti-inflammatory, wherein the steroidal anti-inflammatory is beclomethasone or a pharmaceutically acceptable derivative thereof, said steroidal anti-inflammatory having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.75 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.5 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 2.0 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 3.5 microns; and v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 5.0 microns.
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
(a) about 1 to about 700 mcg a steroidal anti-inflammatory, wherein the steroidal anti-inflammatory is beclomethasone or a pharmaceutically acceptable derivative thereof, said steroidal anti-inflammatory having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.75 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.5 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 2.0 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 3.5 microns; and v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 5.0 microns.
wherein said formulation is suitable for administration to the nasal-paranasal mucosa.
47. The method of claims 45 or 46, further comprising the step of treating the mammal with an antifungal agent selected from the group consisting of amphotericin .beta., fluconazole, and itraconazole.
48. The method of claim 47, wherein said formulation comprises about 4 mg to about 30 mg of amphotericin .beta..
49. The method of claim 47, wherein said formulation comprises about 10 mg of amphotericin .beta..
50. The method of claim 47, wherein said formulation comprises about 20 to about 70 mg of fluconazole or itraconazole.
51. The method of claim 47, wherein said formulation comprises about 30 mg of fluconazole or itraconazole.
52. The method of claim 45, wherein said formulation comprises about 25 to about 400 mcg of said steroidal anti-inflammatory.
53. The method of claim 52, wherein the steroidal anti-inflammatory has the following particle size distribution profile:
i. about 10% or less of the steroidal anti-inflammatory particles have a particle size of less than 0.90 microns;
ii. about 25% or less of the steroidal anti-inflammatory particles have a particle size of less than 1.6 microns;
iii. about 50% or less of the steroidal anti-inflammatory particles have a particle size of less than 3.2 microns;
iv. about 75% or less of the steroidal anti-inflammatory particles have a particle size of less than 6.10 microns; and, v. about 90% or less of the steroidal anti-inflammatory particles have a particle size of less than 10 microns.
i. about 10% or less of the steroidal anti-inflammatory particles have a particle size of less than 0.90 microns;
ii. about 25% or less of the steroidal anti-inflammatory particles have a particle size of less than 1.6 microns;
iii. about 50% or less of the steroidal anti-inflammatory particles have a particle size of less than 3.2 microns;
iv. about 75% or less of the steroidal anti-inflammatory particles have a particle size of less than 6.10 microns; and, v. about 90% or less of the steroidal anti-inflammatory particles have a particle size of less than 10 microns.
54. The method of claim 52, wherein the steroidal anti-inflammatory is fluticasone propionate having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.50 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size less than 0.90 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size less than 1.7 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size less than. 3.5 microns; and, v. about 90% of the steroidal anti-inflammatory particles have a particle size less than 5.5 microns.
i. about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.50 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size less than 0.90 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size less than 1.7 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size less than. 3.5 microns; and, v. about 90% of the steroidal anti-inflammatory particles have a particle size less than 5.5 microns.
55. The method of claim 46, wherein said formulation comprises about 0.2 to about 3 mg of said steroidal anti-inflammatory.
56. The method of claim 46, wherein said formulation comprises about 0.8 mg of said steroidal anti-inflammatory.
57. The method of claim 55, wherein the steroidal anti-inflammatory has the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.35 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 0.70 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 1.25 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 2.0 microns;
v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 3.0 microns; and, vi. greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size of less than 6.5 microns.
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.35 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 0.70 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 1.25 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 2.0 microns;
v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 3.0 microns; and, vi. greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size of less than 6.5 microns.
58. The method of claim. 55, wherein the steroidal anti-inflammatory is beclomethasone dipropionate having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.60 microns;
ii. 25% of the steroidal anti-inflammatory particles have a particle size less than 0.90 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size less than 1.5 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size less than 2.5 microns;
v. about 90% of the steroidal anti-inflammatory particles have a particle size less than 3.5 microns; and, vi. greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size less than 6.0 microns.
i. about 10% of the steroidal anti-inflammatory particles have a particle size less than 0.60 microns;
ii. 25% of the steroidal anti-inflammatory particles have a particle size less than 0.90 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size less than 1.5 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size less than 2.5 microns;
v. about 90% of the steroidal anti-inflammatory particles have a particle size less than 3.5 microns; and, vi. greater than 90% or about 100% of the steroidal anti-inflammatory particles have a particle size less than 6.0 microns.
59. The method of claim 45 or 46, wherein the formulation is a sterile aqueous suspension or aqueous solution.
60. The method of claim 59, wherein the formulation is in a metered-dose spray pump bottle.
61. The method of claim 60, wherein the formulation is administered to said mammal as one spray in each nostril from 1 to about 10 times per day.
62. The method of claim 45 or 46wherein said formulation is administered topically to the nasal-paranasal mucosa of said mammal from 1 to about 10 times per day.
63. The method of claim 45 or 46, further comprising the step of administering an antibiotic to said mammal, wherein said mammal is diagnosed with a bacterial infection of the nasal-paranasal mucosa.
64. The method of claim 63, wherein the antibiotic is administered orally.
65. The method of claim 63, wherein the antibiotic is administered intranasally.
66. The method of claim 65, wherein the antibiotic is neomycin sulfate.
67. The method of claim 45 or 46, wherein said formulation further comprises an antibiotic.
68. The method of claim 67, wherein the formulation comprises about 1 to about 800 mg of neomycin sulfate.
69. The formulation of claim 67, wherein the formulation comprises about 50 to about 300 mg of neomycin sulfate.
70. The method of claim 67, wherein the formulation is a sterile aqueous suspension or aqueous solution in a metered-dose spray pump bottle, and wherein the formulation is administered to said mammal as one spray in each nostril from 1 to about times per day.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/414,756 US7811606B2 (en) | 2003-04-16 | 2003-04-16 | Nasal pharmaceutical formulations and methods of using the same |
US10/414,682 US9808471B2 (en) | 2003-04-16 | 2003-04-16 | Nasal pharmaceutical formulations and methods of using the same |
US10/414,756 | 2003-04-16 | ||
US10/414,682 | 2003-04-16 | ||
US10/657,550 | 2003-09-04 | ||
US10/657,550 US8912174B2 (en) | 2003-04-16 | 2003-09-04 | Formulations and methods for treating rhinosinusitis |
PCT/EP2004/003316 WO2004091576A1 (en) | 2003-04-16 | 2004-03-29 | Formulations and methods for treating rhinosinusitis |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2522294A1 true CA2522294A1 (en) | 2004-10-28 |
CA2522294C CA2522294C (en) | 2014-05-06 |
Family
ID=33303857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2522294A Expired - Fee Related CA2522294C (en) | 2003-04-16 | 2004-03-29 | Formulations and methods for treating rhinosinusitis |
Country Status (11)
Country | Link |
---|---|
US (5) | US8912174B2 (en) |
EP (1) | EP1613282B1 (en) |
JP (1) | JP4718445B2 (en) |
KR (1) | KR101396262B1 (en) |
BR (1) | BRPI0409348B8 (en) |
CA (1) | CA2522294C (en) |
HK (1) | HK1089676A1 (en) |
MX (2) | MX364708B (en) |
PL (1) | PL222059B1 (en) |
RU (1) | RU2410083C2 (en) |
WO (1) | WO2004091576A1 (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
AU2004222340B2 (en) | 2003-03-14 | 2009-11-12 | Intersect Ent, Inc. | Sinus delivery of sustained release therapeutics |
US9808471B2 (en) | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
CA2550811C (en) * | 2003-12-24 | 2012-05-01 | Jane Hirsh | Temperature-stable formulations, and methods of development thereof |
RS51335B (en) * | 2004-01-21 | 2011-02-28 | Schering Corporation | Method of treating acute rhinosinusitis |
PL1750683T3 (en) * | 2004-04-23 | 2013-05-31 | Amgen Inc | Sustained release formulations |
KR100675379B1 (en) * | 2005-01-25 | 2007-01-29 | 삼성전자주식회사 | Printing system and printing method |
KR101523091B1 (en) | 2005-03-23 | 2015-05-26 | 오클루스 이노바티브 사이언시즈 인코포레이티드 | Method of treating skin ulcers using oxidative reductive potential water solution |
EP2298318A1 (en) * | 2005-04-04 | 2011-03-23 | Sinexus, Inc. | Device and methods for treating paranasal sinus conditions |
US8337814B2 (en) * | 2005-12-15 | 2012-12-25 | Topical Sinus Therapeutics, Inc. | Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions |
AU2007205861B2 (en) * | 2006-01-20 | 2013-05-09 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing sinusitis with oxidative reductive potential water solution |
US8535707B2 (en) * | 2006-07-10 | 2013-09-17 | Intersect Ent, Inc. | Devices and methods for delivering active agents to the osteomeatal complex |
US20100323998A1 (en) * | 2007-08-06 | 2010-12-23 | Glenmark Pharmaceuticals Ltd. | Topical composition containing the combination of mupirocin and beclomethasone |
WO2009037855A1 (en) * | 2007-09-21 | 2009-03-26 | Nihon Kodoiryo Kenkyukai Co., Ltd. | Oral and skin compositions |
CN101945621B (en) | 2007-12-18 | 2014-06-18 | 因特尔赛克特耳鼻喉公司 | Self-expanding devices and methods therefor |
EP2303265B1 (en) * | 2008-06-06 | 2014-12-10 | Glenmark Pharmaceuticals Limited | Stable topical formulation comprising voriconazole |
CA2732355A1 (en) | 2008-08-01 | 2010-02-04 | Intersect Ent, Inc. | Methods and devices for crimping self-expanding devices |
US20140336463A1 (en) * | 2009-03-16 | 2014-11-13 | Alan H. Shikani | Rhinotopic therapy for the treatment of chronic rhinosinusitis biofilm disruption, treatment of mucosal granulation and sinus polyps |
US10357640B2 (en) * | 2009-05-15 | 2019-07-23 | Intersect Ent, Inc. | Expandable devices and methods for treating a nasal or sinus condition |
MX348304B (en) | 2009-06-15 | 2017-06-02 | Invekra S A P I De C V | Solution containing hypochlorous acid and methods of using same. |
US8431539B2 (en) * | 2009-09-17 | 2013-04-30 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
JP6041673B2 (en) | 2009-11-23 | 2016-12-14 | キュービスト ファーマシューティカルズ リミテッド ライアビリティ カンパニー | Lipopeptide composition and related methods |
US8916171B2 (en) | 2010-04-27 | 2014-12-23 | Topical Sinus Therapeutics, Inc. | Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis |
DE102010048604A1 (en) | 2010-10-15 | 2012-04-19 | Automotive Lighting Reutlingen Gmbh | Method and electrical circuit for operating a light source of a motor vehicle headlight with direct current, and light module of a motor vehicle headlight with such a circuit and motor vehicle headlights with such a light module |
EP2502616A1 (en) * | 2011-03-21 | 2012-09-26 | Matthew Krayenbuhl | Pharmaceutical nasal composition |
CN103501791B (en) * | 2011-05-03 | 2016-05-18 | 奇斯药制品公司 | For passing through the improvement corticosteroid suspension formulation of inhalation |
US10881698B2 (en) | 2012-01-27 | 2021-01-05 | The Trustees Of The University Of Pennsylvania | Diagnosis and treatment for respiratory tract diseases |
EP2938339B1 (en) * | 2012-12-27 | 2020-08-19 | Massachusetts Eye & Ear Infirmary | Treatment of rhinosinusitis with p-glycoprotein inhibitors |
US20140242040A1 (en) * | 2013-02-23 | 2014-08-28 | Stemnion, Inc. | Methods for preventing and/or treating nasal polyps and rhinosinusitis |
CA2903848C (en) | 2013-03-14 | 2022-03-29 | Intersect Ent, Inc. | Systems, devices, and method for treating a sinus condition |
KR20160030879A (en) * | 2013-04-25 | 2016-03-21 | 씨차드 파마슈티칼즈 인코포레이티드 | Oral Cefepime Compositions and Uses Thereof |
US9078853B2 (en) | 2013-06-18 | 2015-07-14 | Cmpd Licensing, Llc | Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders |
US9370483B2 (en) | 2013-09-13 | 2016-06-21 | Glenmark Specialty S.A. | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
US9937189B2 (en) * | 2013-09-13 | 2018-04-10 | Glenmark Specialty S.A. | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
PT3043773T (en) * | 2013-09-13 | 2021-10-04 | Glenmark Specialty Sa | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
US10548907B2 (en) | 2013-10-04 | 2020-02-04 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
US10758550B2 (en) | 2013-10-04 | 2020-09-01 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
US10653661B2 (en) | 2013-10-04 | 2020-05-19 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
EP4272839A3 (en) | 2013-10-04 | 2024-01-03 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
US10016443B2 (en) | 2013-10-04 | 2018-07-10 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
US11679210B2 (en) | 2014-10-03 | 2023-06-20 | Glenmark Specialty S.A. | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
US10751317B2 (en) | 2014-10-08 | 2020-08-25 | Pacific Northwest Research Institute | Methods and compositions for increasing the potency of antifungal agents |
RU2564006C1 (en) * | 2014-12-03 | 2015-09-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО РостГМУ Минздрава России) | Method of treating patients with rhinosinusitis |
US9744192B2 (en) * | 2015-03-16 | 2017-08-29 | Lee A. Flippin | Methods of treating chronic rhinosinusitis |
US11408900B2 (en) | 2016-01-15 | 2022-08-09 | Massachusetts Eye And Ear Infirmary | Secreted P-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis |
US20200000751A1 (en) * | 2016-05-17 | 2020-01-02 | Proponent Biotech Gmbh | Carboxylic acids for treating/preventing nasal congestion |
US20180071281A1 (en) * | 2016-08-19 | 2018-03-15 | Gerbe Labs Inc. | Treating chronic rhinosinusitis |
US10966946B2 (en) | 2016-11-17 | 2021-04-06 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
US9999604B2 (en) | 2016-11-17 | 2018-06-19 | Cmpd Licensing, Llc | Compounded solutions of diclofenac and lidocaine and methods |
US11737975B2 (en) | 2016-11-17 | 2023-08-29 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
US10525025B2 (en) | 2016-11-17 | 2020-01-07 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
KR102581802B1 (en) * | 2016-11-21 | 2023-09-25 | 삼성전자주식회사 | Display apparatus, system and recording media |
EA033231B1 (en) * | 2017-02-17 | 2019-09-30 | Государственное Учреждение "Республиканский Научно-Практический Центр Оториноларингологии" (Рнпц Оториноларингологии) | Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad |
KR20200060424A (en) * | 2017-09-20 | 2020-05-29 | 아토픽 메디컬, 엘엘씨. | Compositions and methods for the treatment and improvement of respiratory diseases and mucosal inflammation |
Family Cites Families (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2989437A (en) | 1955-06-08 | 1961-06-20 | Upjohn Co | Anti-inflammatory and anti-bacterial decongestant nasal spray compositions |
US3091569A (en) | 1960-08-26 | 1963-05-28 | Mead Johnson & Co | Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus |
GB2107715B (en) | 1981-10-19 | 1985-11-13 | Glaxo Group Ltd | Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it |
GB8432063D0 (en) | 1984-12-19 | 1985-01-30 | Riker Laboratories Inc | Physically modified steroids |
US4674319A (en) * | 1985-03-20 | 1987-06-23 | The Regents Of The University Of California | Integrated circuit sensor |
US4665610A (en) * | 1985-04-22 | 1987-05-19 | Stanford University | Method of making a semiconductor transducer having multiple level diaphragm structure |
EP0579260A1 (en) | 1987-07-07 | 1994-01-19 | Beecham Group Plc | Use of a vasodilator for the treatment of pulmonary hypertension and/or right heart failure-related conditions |
AU610175B2 (en) | 1988-05-25 | 1991-05-16 | Biogal Gyogyszergyar | Pharmaceutical composition comprising a compound containing sulfhydryl group(s) for the treatment of otitis |
JPH03165833A (en) | 1989-02-28 | 1991-07-17 | Isamu Horikoshi | Novel suspending method and composite obtained thereby |
CA2010894A1 (en) | 1989-02-28 | 1990-08-31 | Isamu Horikoshi | Method of forming a suspension and composition formed by said method |
US4990462A (en) * | 1989-04-12 | 1991-02-05 | Advanced Micro Devices, Inc. | Method for coplanar integration of semiconductor ic devices |
SE9000207L (en) | 1990-01-22 | 1991-07-23 | Nobel Chemicals Ab | MEDICINAL PRODUCTS AND THE USE OF THE SAME |
US5620931A (en) * | 1990-08-17 | 1997-04-15 | Analog Devices, Inc. | Methods for fabricating monolithic device containing circuitry and suspended microstructure |
US5417111A (en) * | 1990-08-17 | 1995-05-23 | Analog Devices, Inc. | Monolithic chip containing integrated circuitry and suspended microstructure |
DE19875032I2 (en) | 1990-09-10 | 2007-04-19 | Schering Corp | Mometasone furoate monohydrate, process for its preparation and pharmaceutical compositions containing the same |
US5587735A (en) * | 1991-07-24 | 1996-12-24 | Hitachi, Ltd. | Video telephone |
US5174475A (en) | 1991-03-26 | 1992-12-29 | Glaxo Inc. | Sequential dosing of antifungal and antiinflammatory compositions |
JP3367113B2 (en) * | 1992-04-27 | 2003-01-14 | 株式会社デンソー | Acceleration sensor |
US5461916A (en) * | 1992-08-21 | 1995-10-31 | Nippondenso Co., Ltd. | Mechanical force sensing semiconductor device |
US5491604A (en) * | 1992-12-11 | 1996-02-13 | The Regents Of The University Of California | Q-controlled microresonators and tunable electronic filters using such resonators |
US6199874B1 (en) * | 1993-05-26 | 2001-03-13 | Cornell Research Foundation Inc. | Microelectromechanical accelerometer for automotive applications |
US5616514A (en) * | 1993-06-03 | 1997-04-01 | Robert Bosch Gmbh | Method of fabricating a micromechanical sensor |
US5593688A (en) | 1993-06-25 | 1997-01-14 | Nexstar Pharmaceuticals, Inc. | Liposomal targeting of ischemic tissue |
JPH0753358A (en) | 1993-08-17 | 1995-02-28 | Teijin Ltd | Inhalant |
GB9410222D0 (en) | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
DE4419844B4 (en) * | 1994-06-07 | 2009-11-19 | Robert Bosch Gmbh | accelerometer |
US5613611A (en) * | 1994-07-29 | 1997-03-25 | Analog Devices, Inc. | Carrier for integrated circuit package |
US5510156A (en) * | 1994-08-23 | 1996-04-23 | Analog Devices, Inc. | Micromechanical structure with textured surface and method for making same |
US5517123A (en) * | 1994-08-26 | 1996-05-14 | Analog Devices, Inc. | High sensitivity integrated micromechanical electrostatic potential sensor |
DE4442033C2 (en) * | 1994-11-25 | 1997-12-18 | Bosch Gmbh Robert | Yaw rate sensor |
US5640039A (en) * | 1994-12-01 | 1997-06-17 | Analog Devices, Inc. | Conductive plane beneath suspended microstructure |
US6113894A (en) | 1995-01-23 | 2000-09-05 | Smith; S. Gregory | Ophthalmic compositions and process of using |
DE19503236B4 (en) * | 1995-02-02 | 2006-05-24 | Robert Bosch Gmbh | Sensor made of a multilayer substrate |
FR2732467B1 (en) * | 1995-02-10 | 1999-09-17 | Bosch Gmbh Robert | ACCELERATION SENSOR AND METHOD FOR MANUFACTURING SUCH A SENSOR |
DE19509868A1 (en) * | 1995-03-17 | 1996-09-19 | Siemens Ag | Micromechanical semiconductor component |
IT1275955B1 (en) | 1995-03-22 | 1997-10-24 | Dompe Spa | PHARMACEUTICAL FORMULATIONS IN THE FORM OF THISSOTROPIC GEL |
US5504026A (en) * | 1995-04-14 | 1996-04-02 | Analog Devices, Inc. | Methods for planarization and encapsulation of micromechanical devices in semiconductor processes |
DE19526903B4 (en) * | 1995-07-22 | 2005-03-10 | Bosch Gmbh Robert | Yaw rate sensor |
DE19530007C2 (en) * | 1995-08-16 | 1998-11-26 | Bosch Gmbh Robert | Yaw rate sensor |
WO1997008950A1 (en) | 1995-09-07 | 1997-03-13 | Fuisz Technologies, Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
DE19539049A1 (en) * | 1995-10-20 | 1997-04-24 | Bosch Gmbh Robert | Process for the production of a Coriolis rotation rate sensor |
JPH09115999A (en) * | 1995-10-23 | 1997-05-02 | Denso Corp | Semiconductor integrated circuit device |
US5761957A (en) * | 1996-02-08 | 1998-06-09 | Denso Corporation | Semiconductor pressure sensor that suppresses non-linear temperature characteristics |
US5818227A (en) * | 1996-02-22 | 1998-10-06 | Analog Devices, Inc. | Rotatable micromachined device for sensing magnetic fields |
US5880369A (en) * | 1996-03-15 | 1999-03-09 | Analog Devices, Inc. | Micromachined device with enhanced dimensional control |
JP3423855B2 (en) * | 1996-04-26 | 2003-07-07 | 株式会社デンソー | Electronic component mounting structure and electronic component mounting method |
DE19617666B4 (en) * | 1996-05-03 | 2006-04-20 | Robert Bosch Gmbh | Micromechanical rotation rate sensor |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US5992233A (en) * | 1996-05-31 | 1999-11-30 | The Regents Of The University Of California | Micromachined Z-axis vibratory rate gyroscope |
US5958378A (en) | 1996-07-03 | 1999-09-28 | Research Development Foundation | High dose liposomal aerosol formulations containing cyclosporin A or budesonide |
US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
TW416953B (en) * | 1996-09-25 | 2001-01-01 | Takeda Chemical Industries Ltd | Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use |
JP3584635B2 (en) * | 1996-10-04 | 2004-11-04 | 株式会社デンソー | Semiconductor device and manufacturing method thereof |
FR2756739B1 (en) | 1996-12-05 | 2000-04-28 | Astra Ab | NEW BUDESONIDE FORMULATION |
DE19653969A1 (en) | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | New aqueous pharmaceutical preparation for the production of propellant-free aerosols |
TW503113B (en) * | 1997-01-16 | 2002-09-21 | Senju Pharma Co | Aqueous suspension for nasal administration |
US6191007B1 (en) * | 1997-04-28 | 2001-02-20 | Denso Corporation | Method for manufacturing a semiconductor substrate |
US6388279B1 (en) * | 1997-06-11 | 2002-05-14 | Denso Corporation | Semiconductor substrate manufacturing method, semiconductor pressure sensor and manufacturing method thereof |
US6199430B1 (en) * | 1997-06-17 | 2001-03-13 | Denso Corporation | Acceleration sensor with ring-shaped movable electrode |
US6048774A (en) * | 1997-06-26 | 2000-04-11 | Denso Corporation | Method of manufacturing dynamic amount semiconductor sensor |
JP3555388B2 (en) * | 1997-06-30 | 2004-08-18 | 株式会社デンソー | Semiconductor yaw rate sensor |
US5928207A (en) * | 1997-06-30 | 1999-07-27 | The Regents Of The University Of California | Microneedle with isotropically etched tip, and method of fabricating such a device |
AUPP653898A0 (en) * | 1998-10-16 | 1998-11-05 | Silverbrook Research Pty Ltd | Micromechanical device and method (ij46F) |
EP1033991B1 (en) | 1997-10-09 | 2002-04-17 | Schering Corporation | Mometasone furoate suspensions for nebulization |
KR100883149B1 (en) | 1997-10-22 | 2009-02-10 | 젠스 포니카우 | Use of antifungal agents for the topical treatment of fungus-induced mucositis |
JP3386349B2 (en) | 1997-10-30 | 2003-03-17 | 帝人株式会社 | Aqueous suspension pharmaceutical composition |
SE9704186D0 (en) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
JP3900644B2 (en) * | 1998-01-16 | 2007-04-04 | 株式会社デンソー | Manufacturing method of semiconductor pressure sensor |
US6065341A (en) * | 1998-02-18 | 2000-05-23 | Denso Corporation | Semiconductor physical quantity sensor with stopper portion |
DE19817311B4 (en) * | 1998-04-18 | 2007-03-22 | Robert Bosch Gmbh | Manufacturing method for micromechanical component |
US6423423B2 (en) | 1998-05-06 | 2002-07-23 | Calsonic Kansei Corporation | Formed strip and roll forming |
US6389899B1 (en) * | 1998-06-09 | 2002-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | In-plane micromachined accelerometer and bridge circuit having same |
US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
JP3309808B2 (en) * | 1998-08-04 | 2002-07-29 | 株式会社デンソー | Pressure detector |
WO2000012063A1 (en) | 1998-08-26 | 2000-03-09 | Teijin Limited | Powdery pernasal compositions |
US6204085B1 (en) * | 1998-09-15 | 2001-03-20 | Texas Instruments Incorporated | Reduced deformation of micromechanical devices through thermal stabilization |
IT1303692B1 (en) | 1998-11-03 | 2001-02-23 | Chiesi Farma Spa | PROCEDURE FOR THE PREPARATION OF SUSPENSIONS OF PARTICLES OF DRUGS TO BE ADMINISTERED BY INHALATION. |
US20040141925A1 (en) | 1998-11-12 | 2004-07-22 | Elan Pharma International Ltd. | Novel triamcinolone compositions |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6534340B1 (en) * | 1998-11-18 | 2003-03-18 | Analog Devices, Inc. | Cover cap for semiconductor wafer devices |
US6210988B1 (en) * | 1999-01-15 | 2001-04-03 | The Regents Of The University Of California | Polycrystalline silicon germanium films for forming micro-electromechanical systems |
US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
US6507044B1 (en) * | 1999-03-25 | 2003-01-14 | Advanced Micro Devices, Inc. | Position-selective and material-selective silicon etching to form measurement structures for semiconductor fabrication |
JP4389326B2 (en) * | 1999-05-06 | 2009-12-24 | 株式会社デンソー | Pressure sensor |
WO2000074699A1 (en) | 1999-06-03 | 2000-12-14 | Johnson & Johnson Consumer France Sas | Extracts of feverfew (tanacetum parthenium) against inflammatory disorders |
JP2001002589A (en) | 1999-06-18 | 2001-01-09 | Teijin Ltd | Composition for nasal administration enabling mild raising of medicine blood concentration |
US20020061281A1 (en) | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
AU6076200A (en) | 1999-07-08 | 2001-01-30 | Johnson & Johnson Consumer Companies, Inc. | Exothermic bandage |
US6230567B1 (en) * | 1999-08-03 | 2001-05-15 | The Charles Stark Draper Laboratory, Inc. | Low thermal strain flexure support for a micromechanical device |
GB9918559D0 (en) | 1999-08-07 | 1999-10-06 | Glaxo Wellcome Kk | Novel pharmaceutical formulation |
AU6852900A (en) | 1999-08-20 | 2001-03-19 | Norton Healthcare Ltd | Method to produce powders for pulmonary or nasal administration |
US6386032B1 (en) * | 1999-08-26 | 2002-05-14 | Analog Devices Imi, Inc. | Micro-machined accelerometer with improved transfer characteristics |
EP1083144B1 (en) * | 1999-09-10 | 2008-05-07 | STMicroelectronics S.r.l. | Micro-electromechanical structure insensitive to mechanical stresses. |
US6512255B2 (en) * | 1999-09-17 | 2003-01-28 | Denso Corporation | Semiconductor pressure sensor device having sensor chip covered with protective member |
GB9925934D0 (en) | 1999-11-03 | 1999-12-29 | Glaxo Group Ltd | Novel apparatus and process |
US6524890B2 (en) * | 1999-11-17 | 2003-02-25 | Denso Corporation | Method for manufacturing semiconductor device having element isolation structure |
FI20002217A (en) | 1999-12-30 | 2001-07-01 | Orion Yhtymae Oyj | inhalation particles |
KR100327596B1 (en) * | 1999-12-31 | 2002-03-15 | 박종섭 | Method for fabricating contact plug of semiconductor device using Selective Epitaxial Growth of silicon process |
US6352935B1 (en) * | 2000-01-18 | 2002-03-05 | Analog Devices, Inc. | Method of forming a cover cap for semiconductor wafer devices |
US6507082B2 (en) * | 2000-02-22 | 2003-01-14 | Texas Instruments Incorporated | Flip-chip assembly of protected micromechanical devices |
US6392144B1 (en) * | 2000-03-01 | 2002-05-21 | Sandia Corporation | Micromechanical die attachment surcharge |
GB0009605D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
US6373007B1 (en) * | 2000-04-19 | 2002-04-16 | The United States Of America As Represented By The Secretary Of The Air Force | Series and shunt mems RF switch |
JP2001326367A (en) * | 2000-05-12 | 2001-11-22 | Denso Corp | Sensor and method for manufacturing the same |
US6396711B1 (en) * | 2000-06-06 | 2002-05-28 | Agere Systems Guardian Corp. | Interconnecting micromechanical devices |
US20020013331A1 (en) | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
GB0016040D0 (en) | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
JP2004503593A (en) | 2000-07-14 | 2004-02-05 | アラーガン、インコーポレイテッド | Compositions comprising a therapeutically active ingredient with increased solubility |
US6508126B2 (en) * | 2000-07-21 | 2003-01-21 | Denso Corporation | Dynamic quantity sensor having movable and fixed electrodes with high rigidity |
US6521965B1 (en) * | 2000-09-12 | 2003-02-18 | Robert Bosch Gmbh | Integrated pressure sensor |
US6621137B1 (en) * | 2000-10-12 | 2003-09-16 | Intel Corporation | MEMS device integrated chip package, and method of making same |
US6608054B2 (en) * | 2001-03-20 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and endothelin antagonists |
CA2436814A1 (en) | 2000-12-01 | 2002-07-18 | Nephros Therapeutics, Inc. | Intravascular drug delivery device and use therefor |
US6759273B2 (en) * | 2000-12-05 | 2004-07-06 | Analog Devices, Inc. | Method and device for protecting micro electromechanical systems structures during dicing of a wafer |
DE10060890C2 (en) | 2000-12-07 | 2003-04-03 | Meta Motoren Energietech | Device for switching the operation of a charge exchange valve of an internal combustion engine |
JP3964184B2 (en) * | 2000-12-28 | 2007-08-22 | 株式会社デンソー | Multilayer piezoelectric actuator |
US20020132803A1 (en) | 2001-01-05 | 2002-09-19 | Mahendra Dedhiya | Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus |
US20030008012A1 (en) | 2001-02-05 | 2003-01-09 | Pena Lorraine E. | Composition for rectal delivery of an oxazolidinone antibacterial drug |
US6555904B1 (en) * | 2001-03-05 | 2003-04-29 | Analog Devices, Inc. | Electrically shielded glass lid for a packaged device |
GB0105560D0 (en) | 2001-03-07 | 2001-04-25 | Glaxo Group Ltd | Pharmaceutical formulations |
EP1427407A4 (en) | 2001-03-23 | 2005-05-11 | Luitpold Pharm Inc | Fatty amine drug conjugates |
ATE556706T1 (en) | 2001-03-23 | 2012-05-15 | Luitpold Pharm Inc | FAT ALCOHOL-DRUG CONJUGATES |
US6531767B2 (en) * | 2001-04-09 | 2003-03-11 | Analog Devices Inc. | Critically aligned optical MEMS dies for large packaged substrate arrays and method of manufacture |
US6552404B1 (en) * | 2001-04-17 | 2003-04-22 | Analog Devices, Inc. | Integratable transducer structure |
US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
AU2002355419A1 (en) | 2001-08-06 | 2003-02-24 | Genomed, Llc | Methods and compositions for treating diseases associated with excesses in ace |
US6508561B1 (en) * | 2001-10-17 | 2003-01-21 | Analog Devices, Inc. | Optical mirror coatings for high-temperature diffusion barriers and mirror shaping |
FR2831446B1 (en) | 2001-10-26 | 2004-03-05 | Sanofi Synthelabo | USE OF IRBESARTAN FOR THE PREPARATION OF MEDICINES USEFUL FOR THE PREVENTION OR TREATMENT OF PULMONARY HYPERTENSION |
KR20030045246A (en) | 2001-12-01 | 2003-06-11 | 엘지전자 주식회사 | Specific function excution method and apparatus for portable terminal device |
US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
ITMI20022674A1 (en) | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | PROCEDURE FOR THE PREPARATION OF STERILE FORMULATIONS BASED ON MICRONIZED CRYSTALLINE PHARMACEUTICAL ACTIVE SUBSTANCES TO BE ADMINISTERED AS WATER SUSPENSION BY INHALATION. |
US20040208833A1 (en) | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
US9808471B2 (en) | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US7811606B2 (en) | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
-
2003
- 2003-09-04 US US10/657,550 patent/US8912174B2/en not_active Expired - Fee Related
-
2004
- 2004-03-29 BR BRPI0409348A patent/BRPI0409348B8/en not_active IP Right Cessation
- 2004-03-29 PL PL377855A patent/PL222059B1/en unknown
- 2004-03-29 MX MX2013007993A patent/MX364708B/en unknown
- 2004-03-29 KR KR1020057019698A patent/KR101396262B1/en active IP Right Grant
- 2004-03-29 EP EP04724018.9A patent/EP1613282B1/en not_active Expired - Lifetime
- 2004-03-29 CA CA2522294A patent/CA2522294C/en not_active Expired - Fee Related
- 2004-03-29 RU RU2005135333/15A patent/RU2410083C2/en active
- 2004-03-29 JP JP2006504903A patent/JP4718445B2/en not_active Expired - Lifetime
- 2004-03-29 WO PCT/EP2004/003316 patent/WO2004091576A1/en active Application Filing
- 2004-03-29 MX MXPA05011106A patent/MXPA05011106A/en active IP Right Grant
-
2005
- 2005-03-12 US US11/078,263 patent/US8309061B2/en active Active
- 2005-10-14 US US11/250,925 patent/US8129364B2/en not_active Expired - Fee Related
-
2006
- 2006-09-15 HK HK06110220.5A patent/HK1089676A1/en not_active IP Right Cessation
-
2007
- 2007-10-31 US US11/931,484 patent/US8663695B2/en not_active Expired - Fee Related
-
2012
- 2012-02-08 US US13/368,873 patent/US9180126B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2005135333A (en) | 2006-03-20 |
CA2522294C (en) | 2014-05-06 |
US9180126B2 (en) | 2015-11-10 |
RU2410083C2 (en) | 2011-01-27 |
US20040209852A1 (en) | 2004-10-21 |
WO2004091576A1 (en) | 2004-10-28 |
JP4718445B2 (en) | 2011-07-06 |
US8663695B2 (en) | 2014-03-04 |
US20080058296A1 (en) | 2008-03-06 |
BRPI0409348B1 (en) | 2019-04-24 |
US8309061B2 (en) | 2012-11-13 |
KR101396262B1 (en) | 2014-05-19 |
MX364708B (en) | 2019-05-06 |
EP1613282B1 (en) | 2018-05-02 |
US20120237559A1 (en) | 2012-09-20 |
PL377855A1 (en) | 2006-02-20 |
MXPA05011106A (en) | 2005-12-12 |
BRPI0409348A (en) | 2006-04-25 |
US20050180925A1 (en) | 2005-08-18 |
JP2006523631A (en) | 2006-10-19 |
KR20060003019A (en) | 2006-01-09 |
US8912174B2 (en) | 2014-12-16 |
EP1613282A1 (en) | 2006-01-11 |
AU2004229149A1 (en) | 2004-10-28 |
US20060051300A1 (en) | 2006-03-09 |
HK1089676A1 (en) | 2006-12-08 |
PL222059B1 (en) | 2016-06-30 |
BRPI0409348B8 (en) | 2021-05-25 |
US8129364B2 (en) | 2012-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2522294C (en) | Formulations and methods for treating rhinosinusitis | |
ZA200509240B (en) | Formulations and methods for treating rhinosinusitis | |
CA2310222C (en) | New composition of matter | |
US8158154B2 (en) | Nasal pharmaceutical formulations and methods of using the same | |
EP1782839A1 (en) | Sterilization process of Glucocorticosteroid by supercritical CO2 | |
AU2004229149B2 (en) | Formulations and methods for treating rhinosinusitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220329 |